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ABSTRACT 
Capillary electrochromatography (CEC) is a major capillary electrophoresis (CE) mode 
that have been interfaced to mass spectrometry (MS) for sensitive and selective analysis of chiral 
compounds. This research expands CEC applications in cancer biomarker and chiral CE analysis. 
Chapter 1 is a review of liquid chromatography-mass spectrometry (LC/MS), gas chromatography-
mass spectrometry (GC/MS), and capillary electrophoresis mass spectrometry (CE/MS) for 
analysis of metabolites in prostate cancer diagnostics and therapies. In this chapter, a literature 
survey was performed within the databases PubMed, 4 Caplus/Webline and Web of Sciences. A 
total 17 studies reporting on various analytical platforms for metabolite identification in prostate 
cancer research,  which often include case-control comparison were identified and reviewed. 
Chapter 2 described the analysis of metabolite biomarkers in prostate cancer tissues by capillary 
electrochromatography mass spectrometry. In this chapter, a capillary CEC–MS/MS method was 
developed for the simultaneous determination and separation of eight proofs of concept (POC) 
metabolites (betaine, malate, proline, N-acetyl aspartate, N-acetylglucosamine, uracil, xanthine, 
and alanine) as potential prostate cancer diagnostic markers.  A polymeric monolith column with 
a hydrophilic crosslinker and strong anion-exchange mixed-mode has been fabricated by an in situ 
copolymerization of vinyl benzyl trimethylammonium chloride, and bisphenol A glycerolate 
dimethacrylate (BisGMA) in the presence of methanol and dodecyl alcohol as porogens and AIBN 
as initiator.  After CEC separation, samples were analyzed by a triple–quadrupole mass 
spectrometer operated in positive ion mode. After optimization, the data showed that the CEC-
MS/MS method using monolithic column achieved a much better chromatographic selectivity 
compared to coated columns and increased sensitivity than bare fused silica column The effect of 
mobile phase pH, ACN percentage and additive were studies. Under the optimum mobile phase 
conditions, this method was carried out to separate and detect eight metabolites in the biopsy 
sample. The LOD for the metabolites is between 50nM-100nM. This method has successfully used 
to examine patients’ prostate cancer with an accuracy of 95%. Chapter 3 demonstrates Insights 
into Chiral Recognition Mechanisms in CEC using linear salvation energy relationship. By varying 
the linker (amide and carbamate), head group (alanine, leucine, and valine) and chain length (C8, 
C10 and C12) of the amino acid bound surfactants; monolithic column was made to ultimately 
understand the factors governing chiral stationary solid phase. Through the comparison of system 
parameters, we can see that surfactant head group, linker and chain length affect the separation of 
achiral and chiral compounds. Also, with the same type surfactant, data was presented to show 
how the trend of LSER parameters and how it affects separation between in CEC. This study 
showed the predictive capability of LSER to understand the aforementioned intermolecular 
processes controlling retention and by doing so, be able to quantitatively predict the experimental 
conditions to achieve an acceptable chiral separation. 
 INDEX WORDS: Capillary electrochromatography (CEC), Prostate cancer, Metabolites, Cancer 
biomarkers, Chiral separation, Mass spectrometry, Chiral monolithic stationary phases, 
Multivariate design 
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1 CHAPTER 1: Review of Liquid Chromatography-Mass Spectrometry (LC/MS), Gas 
Chromatography-Mass Spectrometry (GC/MS) and Capillary Electrophoresis Mass 
Spectrometry (CE/MS) for Analysis of Metabolites in Prostate Cancer Diagnostics and 
Therapies 
1.1 Abstract 
In this introductory chapter, an overview is presented on a number of important aspects related to 
the analysis of metabolites in prostate cancer research. A literature survey was performed within 
the databases PubMed, 4 Caplus/Webline and Web of Sciences. A total 17 studies reporting on 
various analytical platforms for metabolite identification in prostate cancer research,  which often 
include case-control comparison were identified and reviewed. More particularly, this chapter 
summarizes the present situation with respect to the review of chromatography-mass spectrometry 
platforms, sample type, study type and the type of mass spectrometers used in prostate cancer 
research. Despite current challenges, metabolomics has the potential to evolve into a standard tool 
in prostate cancer. 
1.2 Introduction 
1.2.1 Metabolism, Metabolites, Metabolome and Metabolomics 
Metabolism is a term used to describe a set of chemical reactions of the living organism to sustain 
life. A series of enzyme participate in these reactions to allow cells to grow and reproduce. There 
are two subdivisions of metabolism: catabolism and anabolism.  Catabolism is the breakdown 
procedure of large molecules to obtain energy (e.g., hydrolysis reaction and cellular respiration). 
Conversion from starch to glucose involves hydrolysis and energy are released in the reaction. 
Anabolism, which is a reverse of catabolism, refers to constructive metabolism, in which simpler 
2 
molecules such as various cell components can be combined to form more complex molecules 
such as proteins and nucleic acids resulting in energy storage in these molecules. 
1.2.2 Metabolites: Properties and Function of Metabolite 
Metabolites are a catalytic product of enzyme reactions, which occur inside the cell.  Six major 
factors are considered when classifying a substance as a metabolite.  These six factors in metabolite 
classification include: (a) metabolite formation occurs within the cell (intracellularly); (b) 
metabolites rearrange and react with enzymes; (c) metabolic product must proceed to form another 
species in a subsequent reactions, (d) metabolite have a well-defined half-life and they do not store 
in cells; (e) metabolites serves as a regulator controlling the speed of many metabolisms; (f) 
metabolites serve important biological functions in the cell.    Metabolites are also termed as 
intermediates (intermediate metabolite) and products of metabolism (final metabolite).  When 
metabolites usually refer to the small molecule, they are defined as primary or secondary 
metabolites. Primary metabolites are directly involved in normal cell growth, development, and 
reproduction. (e.g., amino acids metabolism).   On the other hand, secondary metabolites are not 
directly involved in these processes, but may have a long-term effect on human survivability.  
The enzyme is essential for metabolic reactions because the presence of enzyme allow a 
thermodynamically difficult reaction to occur when coupled to another spontaneous reaction. One 
example, which shows the potential of the enzyme is the energy generated from ATP hydrolysis 
to drive another chemical reaction.   Metabolism of an organism determines which substances for 
this organism are nutritious and which are poisonous.  For example, hydrogen sulfide serves as 
nutrition to some prokaryotes, but the same chemical is toxic to animals.1 The speed of metabolism 
3 
reactions, known as the term “metabolic rate,” also affects an organism food demand. For example, 
faster the ATP to ADP conversion rate, the higher will be food demand.  
1.2.3 Characteristics of Metabolism 
Metabolism has a very useful characteristic, i.e., the basic metabolic pathways are similar between 
different species. For example, citric acid (also known as tricarboxylic acid (TCA), is present in 
all organisms, which may be unicellular organisms such as tiny bacteria or even huge multicellular 
organisms such as elephants.2 Such metabolic similarity is due to the high efficiency associated 
with metabolic pathways, and their early appearance in the evolutionary history.3,4 There are 
numerous metabolic pathways. The most important metabolic processes in human includes: citric 
acid cycle (Krebs' cycle), oxidative phosphorylation, pentose phosphate pathway, urea cycle, fatty 
acid β-oxidation, and gluconeogenesis. 
The metabolome is a sum of all small molecules found in a biological sample, e.g., cell, tissue, 
tissue extract, biofluid, organs or even an organism.   Essentially, metabolome involves the 
interaction of an organism genome with its environment.  Therefore, an organism metabolome is 
a good model of its phenotype, which is a product of genotype and its environment. In different 
species, metabolomes are different.   Even in the same species, metabolome differs from each other 
in different organ and tissue.   Metabolome database such as Human Metabolome Database 
(HMDB)5 and Yeast Metabolome Database (YMDB)6 are widely used for metabolite search.   
Metabolomics is a rapidly emerging omics in systems biology involving studies of an entire set of 
metabolites found in cells, tissue or the entire organism.   The metabolites are first identified and 
detected with analytical technologies.  Next, a systematic study is performed to quantitate and 
analyze the concentration of as many metabolites in a biological sample as possible. The term 
4 
metabolomics was first coined by Professor Jeremy Nicholson at Imperial College London in 
1999.7 After the rapid development, metabolomics is now related to a number of areas, such as 
disease diagnosis,8 pharmaceutical research and development, nutrition, food science, drugs 
science, environmental science, botany and human health care.  
Metabolite analysis has been used for many decades in disease diagnosis since Sir Archibald 
Garrod first links metabolism with human disease.9-13 While other –omics, such as transcriptomic 
and proteomics, are well known for their important role in diagnostic and treatment of cancer and 
other diseases, metabolomics is also attracting more and more attention because of its high 
sensitivity to diet, stress and environmental related physiological changes.  In transcriptomic and 
proteomics, the blueprint of tens of more than ten thousand targets is measured to monitor the 
organism functions. However, the metabolomic study is less time consuming because the smallest 
domain (only ~5000 metabolites in metabolism pathways of living organs) compared to other -
omics.14,15 Metabolomics is promising because it involves simple sample preparation procedure 
and ease of data comparison among different conditions.7 In this introduction to dissertation 
chapter, the application of metabolomics in the diagnosis of prostate cancer is discussed.  For 
prostate cancer, there is an urgent need to identify reliable biomarkers as a diagnostic tool for 
effective therapy design. 
1.3 Identification of Studies in Prostate Cancer  
To better understand metabolomics role for prostate cancer, four databases (PubMed, web of 
Science  and CAPLUS/EDLINE) were searched with the following keywords “’Metabolomics’ 
AND ‘Prostate Cancer’” AND “‘CE/MS’, “’Metabolomics’ AND ‘’ Prostate Cancer AND 
‘GC/MS’”, “’Metabolomics’ AND ‘Prostate Cancer’ AND ‘LC/MS’” from 2012 to 2016.  Flow 
5 
charts for the review selection process for metabolites involved in the prostate is shown in Figure 
1.1. We included only studies involving separations [gas chromatography (GC), high-
performance liquid chromatography (HPLC)/ultrahigh pressure liquid chromatography (UPLC) 
or capillary electrophoresis (CE) coupled to mass spectrometry (MS) and approaches using only 
NMR, UV-98 Vis or (MS) were excluded. In addition, only discussions on human plasma, urine, 
CSF or tissue are included in this review.   All duplicate findings were removed. Only papers 
reported in the English language are included in this review.   
 
Figure 1.1 Schematic overview of the search strategy for metabolites in prostate cancer and 
neurological disease. 
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17 articles
(Citation 
Retrived)
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/MEDLINE
16 articles
(Citation 
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“Metabolomics” AND “Prostate Cancer” AND “LC/MS”
or
“Metabolomics” AND “Prostate Cancer” AND “GC/MS”
or
“Metabolomics” AND “Prostate Cancer” AND “CE/MS”
Exclusion of duplicate findings, reviews 
and  papers not meet  criteria
Import to EndNote
17 Articles
62 Articles (Abstract and full text 
retrived)
Web of Science
29 articles
(Citation 
Retrived)
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In total, 17 papers (as listed in Table. 1.1) were reviewed. The information (i.e., sample types, 
study types and analytical platforms) is illustrated in Figures 1.2- 1.5 and each of these topics are 
discussed below.
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Table 1.1 Selected works published during the last 10 years regarding biomarkers of prostate cancer by LC or CE coupled 
to MS using a metabolomics approach. 
Study Disease type Method Sample Metabolites pathway Study type 
Brown 
201241 
Kidney and prostate 
cancer tumor 
UPLC-
LTQ-
MS/MS 
Tissue amino acids, peptides, carbohydrates, 
lipids, nucleotides, cofactors, 
xenobiotics 
Tissue profiling 
Kapoore 
201542 
Cancer GC-q-MS Tissue amino acids, glucose, fatty acids and 
nucleotides 
Metabolomics for 
therapy monitoring 
Hu 201343 prostate cancer GC-ITQ-
MS/MS 
Tissue amino acids, glucose, nucleotides and 
TCA cycle metabolites 
Tissue profiling 
Tripathi 2013 Bladder Cancer and 
Benign Disease 
GC- MS* Tissue Amino acids Tissue profiling 
Brockmoeller 
201244 
Breast Cancer GC-TOF-
MS 
Tissue sn-glycerol-3-phosphate Tissue profiling 
Liu 201545 Prostate Cancer UPLC-
QqQ-
MS/MS 
Tissue crucial steroidogenic enzymes- 
AKR1C3 
Metabolomics for 
case-control 
comparison 
McGinnis 
201340 
prostate cancer UPLC-
qTOF-MS 
Tissue siRNAs Method 
Development 
Troyer 
201346 
prostate cancer LC- MS* Tissue Alanine, betaine, cysteine, malate, N-
acetylaspartate, N-acetylglucosamine, 
proline, uracil, xanthine 
Method 
Development 
8 
Study Disease type Method Sample Metabolites pathway Study type 
Huang 
201447 
prostate cancer LC-QTOF-
MS 
Serum cholesterol metabolic and mitogen-
activated protein kinase signaling 
pathway 
Metabolomics for 
therapy monitoring 
Kami 201239 lung and prostate tumor CE-TOF-
MS 
Tissue lactate, tricarboxylic acid (TCA) cycle 
intermediates, and amino acids 
Tissue profiling 
Nacoulma 
201348 
Lung, breast and 
prostate tumor 
GC-ITQ-
MS 
Tissue Cembrene derivatives, Incensole 
derivatives, glucose, amino acids, 
organic and phenolic acids 
Metabolomics for 
case-control 
comparison 
Wei 201349 Breast cancer LC-QTOF-
MS/MS 
Serum threonine, isoleucine, glutamine and 
linolenic acid 
Metabolomics for 
therapy monitoring 
Sampson 
201331 
Prostate, Lung, 
Colorectal, 
and Ovarian Cancer 
LC-LIT-MS 
and GC-
MS* 
Plasma amino acids, carbohydrates, fatty 
acids, androgens, and xenobiotics 
Metabolomics for 
patient prognosis 
Cross 201420 Colorectal, Prostate, 
Lung, Colorectal, and 
Ovarian Cancer 
GC-MS* Serum amino acids, carbohydrates, fatty 
acids, androgens, and xenobiotics 
Metabolomics for 
patient prognosis 
Li 201550 Prostate cancer LC-LTQ-
Orbitrap-
MS/MS 
Tissue Multiple peptides derived from 
osteopontin 
Metabolomics for 
patient prognosis 
Guertin 
201551 
Prostate, Lung, 
Colorectal, and Ovarian 
Cancer 
UPLC-
MS/MS and 
GC-MS* 
Serum Caffeine-related metabolites Metabolomics for 
case-control 
comparison 
9 
Study Disease type Method Sample Metabolites pathway Study type 
Struck-
Lewicka 
201652 
Prostate cancer LC-TOF-
MS and 
GC-QqQ-
MS/MS 
Urine Urea and tricarboxylic 
acid cycle, amino acid and purine 
metabolism 
Metabolic 
fingerprintin 
 
.
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1.4 Role of Metabolomics in Prostate Cancer 
As mentioned earlier, metabolomics requires analysis of metabolite concentration change in a 
biological sample related to a certain disease.   The biological specimen used in prostate cancer 
diagnostic includes urine, blood, and human tissues; each contains a different type of metabolites 
pathway information. A successful clinicopathologic and demographic evaluation should consider 
the ease of sample handling and preparation, patient demographic, instrumentation and method 
reliability.  For therapy monitoring or case-control comparison studies, a larger sample pool is 
required, and the sample number is usually above 100. No significant difference should be 
observed among the patients in terms of median age, comorbid conditions and menopausal status. 
One typical case is a recent report with a list of over 110 metabolites in prostate cancer tissues.16  
In this study, the sample collection, sample preparation, and metabolite extraction were described, 
and the metabolites belong to different pathways and across all major biomedical classes such as 
amino acid metabolism (proline, cysteine, alanine, histidine, lysine, leucine, serine, N-acetyl-
aspartyl-glutamate (NAG), betaine, N-acetyl aspartate (NAA) etc.), energy metabolism (malic, 
succinate, phosphate etc.), carbonhydrate (glucose, ribose etc.), lipid (choline, cartinine, glycerol 
etc), nucleotide (uracil, uidine, xanthine etc),  cofactors and vitamins (alpha-tocopherol and 
panothenate). The authors applied the histology, metabolomic profiling, and statistical analysis to 
develop and validate the method with GC-MS and LC-MS in a single core needle biopsy to aid 
the prostate cancer diagnosis. The list of metabolites and pathways are shown in Table 1.2. In the 
next sub-sections, some critical aspects of prostate cancer research  such as sample types, study 
types, analytical platforms and MS analyzers will be discussed detailed based on the literature 
survey. 
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Table 1.2 Metabolites in the sub pathways showing significant difference between cancer tumor and benign prostate 
samples.16 
Sub Pathway Biomedical 
Alanine and aspartate metabolism aspartate, alanine 
Benzoate metabolism benzoate, 2-aminobutyrate 
Carnitine metabolism 3-dehydrocarnitine, acetylcarnitine, carnitine, deoxycarnitine 
Cysteine, methionine, SAM, 
taurine metabolism 
Cysteine, cystine, methionine, S-adenosylhomocysteine (SAH) 
Fatty acid metabolism docosapentaenoate (n3 DPA; 22:5n3), docosapentaenoate (n6 DPA; 22:5n6), 
butyrylcarnitine, propionylcarnitine, 4-hydroxybutyrate (GHB) 
gamma-glutamyl gamma-glutamylglutamate, gamma-glutamylglutamine 
Glutamate metabolism N-acetyl-aspartyl-glutamate (NAAG), glutamate 
Glutathione metabolism 5-oxoproline, cysteine-glutathione disulfide, choline, ethanolamine, glycerol 
Glycine, serine and threonine 
metabolism 
Betaine, glycine, serine, threonine 
Glycolysis, gluconeogenesis, 
pyruvate metabolism 
glucose 1-phosphate, glucose 
Histidine metabolism Histidine 
Krebs cycle Fumarate,  malate, succinate 
Long chain fatty acid dihomo-linoleate (20:2n6), eicosenoate (20:1n9 or 11), myristoleate (14:1n5), oleate 
(18:1n9) 
12 
Sub Pathway Biomedical 
Lysine metabolism 2-aminoadipate, lysine 
Lysolipid 1-arachidonoylglycerophosphoethanolamine, 1-rachidonoylglycerophosphoinositol, 1-
linoleoylglycerophosphoethanolamine, 1-oleoylglycerophosphoethanolamine, 1-
leoylglycerophosphoinositol, 1-oleoylglycerophosphoserine, 1-
almitoylglycerophosphoinositol, 1-stearoylglycerophosphoethanolamine, 1-
tearoylglycerophosphoinositol, 2-oleoylglycerophosphoethanolamine, 2-
almitoylglycerophosphoethanolamine 
Medium chain fatty acid caprylate (8:0) 
Nucleotide sugars, pentose 
metabolism 
ribose 
Pantothenate and CoA metabolism pantothenate 
Phenylalanine & tyrosine 
metabolism 
Phenylalanine, tyrosine 
Purine and pyrimidine metabolism methylphosphate 
Purine metabolism Hypoxanthine, inosine, xanthine, xanthosine, adenine, guanosine 
Pyrimidine metabolism Cytidine, pseudouridine, uracil, uridine 
Urea cycle; arginine-, proline-, 
metabolism 
Arginine, ornithine, proline, trans-4-hydroxyproline 
Tryptophan metabolism Tryptophan 
Valine, leucine and isoleucine 
metabolism 
valine 
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1.4.1 Sample Type Investigated for Prostate Cancer  
A total of 17 papers were found in the metabolites analysis for prostate cancer.  A pie diagram 
showing the distribution of sample type investigated for prostate cancer is shown in Figure 1.2.   
The most common sample assessed is tissue sample from tumor biopsy (11, 65%) followed by the 
traditional clinical sample, such as serum, plasma (total 5 studies, 29%), and urine (1 studies, 6%). 
 
Figure 1.2 Pie diagram illustrating the study types used in prostate cancer. The number and 
percentage followed the name of the sample type represent the  number of studies and the 
percentage in our study pool. The same style is employed for other pie charts shown in Figure 
1.3-1.5. 
Among all sample types, urine requires the least sample preparation (only centrifuge and 
dilution)17. In other samples types like tissue and CSF, protein needs to be removed before analysis. 
However, since metabolites concentration could be easily diluted or concentrated in a urine sample 
(sweating, drinking water, etc.), urine is not the best choices in most cases.  
Whole blood, serum, and plasma are the second most routine specimen for prostate cancer. The 
concentration of metabolites in that sample can be related to pharmacological effect and due to 
Serum, 4, 
23%*
Plasma, 1, 
6%
Urine, 1, 
6%
Tissue, 11, 
65%
Sample Type of Prostate Cancer Studies
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different metabolite profiles; In addition, whole blood, serum, and plasma could be used to monitor 
parent metabolites. 18-22   
Sample preparation for the solid sample is more difficult than the liquid samples. For examples, to 
liberate metabolites from complicated membranes and large molecules, tissue samples must be 
sliced with mechanical devices and extract with certain solvent. Moreover, one need to take extra 
care to avoid the leakage of metabolites from other biofluid sources (blood).16,23-26 Nevertheless, 
as tissue sample could provide the widest range of metabolites profiling, the tissue sample is most 
widely used in the prostate cancer metabolomic analysis. 
1.4.2 Study Types Investigated for Prostate Cancer  
Pie chart with different study types distribution is shown in Figure 1.3.  Five studies in tissue 
profiling are reported, and this accounts for 29% in the prostate cancer metabolomic study, which 
means the metabolism in prostate cancer is still not well understood, and new metabolic pathway 
are involved in either the disease pathology or treatment.27 Furthermore, metabolites for therapy 
monitoring and patient prognosis are second most common study types in prostate cancer studies 
(18%) because the stronger demand for early diagnosis and treatment of prostate cancer. 
Metabolomics for case-control comparison is the third most common study types (3, 17%). In this 
last category, instead of independent validation, relative sample concentration change is 
employed.20,26,28-32 Thus, case-control studies will give a clue on the future potential of metabolites 
use as an early diagnostic tool for prostate cancer. Fewer studies (1, 12%) are discussed in method 
development, and most of the studies are not quantitative enough due to the sample type and 
pathway complexity.  
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Figure 1.3 Pie diagram illustrating types of a biological sample used for prostate cancer 
studies. The number and percentage followed the name of the study type represent the 
number of studies and the percentage in our study pool. 
1.4.3 Analytical Platforms based on GC/MS, LC/MS, and CE/MS for Prostate Cancer 
To achieve a better understanding of metabolomic in prostate cancer, multiple analytical platforms 
have been employed, and the distribution for each platform is shown in Figure 1.4.  Gas 
chromatography-MS (GC/MS) is a traditional method of choice and is exclusively studied due to 
its robustness and low ion suppression of mass spectrometer (e.g., single quadrupole).  
GC/MS is widely used in prostate cancer metabolomic study (6, 35%) of both volatile and non-
volatile analytes following derivatization.16,22,25,33-35  Given the excellent selectivity and 
repeatability, modern GC/MS is an ideal tool for complex metabolic samples. However, it should 
be noted that only fewer metabolites can be detected by GC-MS due to the difficulty associated 
with derivatization of polar compounds.  
Metabolomics 
for case-
control 
comparison, 
3, 17%
Metabolomics 
for therapy 
monitoring, 3, 
18%
Metabolomics 
for patient 
prognosis, 3, 
18%
Method 
Development, 
2, 12%
Tissue 
profiling, 5, 
29%
other, 1, 6% 
Study Type of Prostate Cancer Studies
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Figure 1.4 Pie diagram illustrating the types of analytical platforms used for prostate cancer 
studies. The number and percentage followed the name of the analytical platform represent 
the number of studies and the percentage in our study pool. 
The highly polar metabolites analysis relies on more powerful techniques such as high-
performance liquid chromatography (HPLC) and capillary electrophoresis (CE).  The various 
chromatographic modes of HPLC such as ion exchange chromatography (IEC), normal phase 
(NP), reversed-phase (RP) and hydrophilic interaction liquid chromatography (HILIC) may 
employ MS compatible mobile phases. Thus, HPLC (7 studies. 41%) could provide good 
separation of different types of metabolites, give complementary understanding for metabolome 
and is the most popular separation platform for metabolome study to date. A high-resolution and 
more efficient form of HPLC is ultra-high pressure liquid chromatography (UPLC), which has 
superior speed and significantly higher sensitivity compared to conventional HPLC-MS.   Several 
authors have reported a gold standard UPLC-MS because of the high peak capacity and low matrix 
effect.  25,36-38  
CE/MS, 1, 
6%
GC/MS, 6, 
35%LC/MS, 7, 
41%
Two or 
more 
Methods, 
3, 18%
Platform of Prostate Cancer Studies
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To profile different types of metabolites, nearly 18% studies used both LC/MS and GC/MS as 
hyphenated technologies for prostate cancer study. In an outstanding paper, Brown et al. used GC-
MS and LC- MS to analyze methanolic extract in prostate and other biopsy samples. 16 In their 
study authors found 83 metabolites (out of a total of 260 different metabolites) to be promising 
markers.  They connected these metabolites with cellular architecture and immunoreactivity by 
histopathological analysis. The 83 metabolites determined to be different between tumor 
containing sample and non-tumor containing sample among eight patients.   
While only one paper is related to CE-MS in our study pool, it does not mean CE has less potential 
in prostate cancer metabolome. In a study reported by Kami and co-workers, concentration change 
of lactate, focusing on the phosphorylation analysis was found to be helpful in developing more 
effective bio-marker for anticancer therapy.39 Considering the high selectivity, sensitivity and low 
sample demand for biological samples, CE-MS is a promising field to explore the potential of 
metabolites analysis.In addition, with the further advancement of sensitive detection and 
improvement of column technology more sensitive biomarker will be discovered by CE-MS. 
1.4.4 Mass Spectrometer Types Used for Prostate Cancer 
The most common mass analyzer used for metabolite identification is quadrupole time-of-flight 
(qTOF) (12%) and triple quadrupole (QqQ) (17%), as shown in Figure 1.5.   Some paper also used 
Orbitrap alone or combined with quadrupole to get better results. Each MS analyzer has specific 
advantages and drawbacks. Therefore, it is important to use the most suitable MS which provides 
a balance among data quality (sensitivity, accuracy), time and cost consumption as well as research 
demanding (metabolic pathway, sample concentration, and stability). For example, if the research 
demanding is to quantitate the metabolites concentration level, QqQ should be the first choice 
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instead of TOF. Advantages and disadvantages of the aforementioned MS analyzers are discussed 
separately in the following paragraphs.  
 
Figure 1.5 Pie diagram illustrating the types of mass spectrometer used for prostate cancer 
studies. The number and percentage followed the name of the mass spectrometer represent 
the number of studies and the percentage in our study pool. 
As a traditional mass spectrometer in most analytical laboratories, QqQ is widely used in 
metabolites analysis. With excellent tandem MS capability, QqQ could provide information on 
structure determination of product ion, thereby reduce the possible structures, which could be 
applied in non-targeted metabolites profiling. Gaikwad successfully developed a method for more 
than 100 indigenous and exogenous steroid measurements in breast tissue in 12 minutes single 
UPLC-QqQ- MS/MS method. In this study, a simple liquid-liquid extraction was applied to extract 
101 steroids followed by UPLC-MS/MS. The LOD for steroids metabolites is 0.001-15.7 pmol, 
suggesting the potential for clinical diagnosis for early stage prostate cancer. However, the 
linearity was not ideal with correlation coefficients (R2) of only 0.90 for most of the analytes. 25 
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12%
Q, 1, 6%
ITQ, 2, 12%
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Kapoore’s group characterized eleven different classes’ metabolites such as the pathway of amino 
acids, glucose, fatty acids and nucleotides with QqQ. A results showing difference of concentration 
level could aid the metabolomic interpretation and used for the therapy monitoring of prostate 
cancer.40 With QqQ-MS detector, Liu’s group41 found the concentration level of one crucial 
steroidogenic enzyme, AKR1C3, is associated with the enzalutamide resistance and the targeting 
AKR1C3 could potentially increase the survival rate of prostate cancer patients. 
However, due to the compromised duty cycle, quadruple MS loses partial sensitivity when a larger 
number of MS/MS data is acquired. To get more ion information, QqQ sacrifices either dwell time 
or data points collected on each peak.  In contrast, qTOF allows analytes identification with 
accurate mass resolution and detection sensitivity in a rapid scan mode, without the need for 
prefiltration of certain predicted metabolites, which makes qTOF a cost and time effective mass 
analyzer, especially in the non-targeted metabolomic study. A study of the direct determination of 
small ribonucleic acids method was developed by Bartlett’s group with ion exchange column. In 
their study, a set of RNAs in prostate cancer cells was identified with 6 ng/200,000 cells and LOQ 
of 6 ng/mL.   With a one-step sample preparation, the recovery > 95% was obtained.42  In the 
literature review, the qTOF is also most popular mass analyzer (65% in prostate cancer). Orbitrap 
was also discussed in some studies as part of tandem MS. McGinnis’s group developed a method 
to quantitate the metabolites of siRNAs in a tissue sample with qTOF and applied the method for 
the determination of metabolism of and siRNA in prostate cancer.42  Another application of qTOF 
is a study of Huang’s group, in which a set of metabolites in cholesterol metabolic and mitogen-
activated protein kinase signaling pathways were evaluated as a response to endocrine therapy to 
prostate cancer patients.43 A similar prostate cancer therapy monitoring case was reported by Wei’s 
20 
group, in which threonine, isoleucine, glutamine and linolenic acid pathway metabolites was 
studied with LC- QTOF-MS/MS.44 
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2 CHAPTER 2: Method Development and Quantitation of Metabolites in Prostate 
Tissue Samples by Capillary Electochromatography-Mass Spectrometry 
2.1 Abstract 
Prostate cancer is the second “killer”cancer among males worldwide. However, there are only few 
reports for early diagnosis s of prostate cancer. The aim of this project was to develop a quantitative 
capillary electrochromatography coupled to tandem mass spectrometry (CEC-MS/MS) for 
metabolic profiling in prostate needle biopsy extracts, based on extraction and fixation (mPREF) 
technique developed by Troyer’s and coworkers.1 Through a one-step in situ polymerization, a 
modified polymer monolith was successfully synthesized and characterize. With vinylbenzyl 
trimethylammonium chloride (VBTA) as a monomer and a hybrid crosslinker bisphenol a 
glycerolate dimethacrylate (BisGMA) and ethylene glycol dimethacrylate (EDMA), this column 
has strong separation selectivity for hydrophilic metabolites. The effect of mobile phase pH, ACN 
percentage and volatile additive were optimized. The CEC-MS/MS was found to be highly robust 
with limit of detection (LOD) for the metabolites to range between 50 -100 nM. The validated 
CEC-MS/MS method was able to differentiate and quantitate between normal versus tumor tissue 
in 22 human subjects. This method could be s successfully used to examine prostate cancer with 
an accuracy of 95%. 
2.2 Introduction 
One of the most common malignant tumors, prostate cancer1-3 is heterogeneous in clinical settings 
and has a highly variable natural history. For prostate cancer diagnosis and prognosis, the present 
methods have limitations making quantitative information to be valuable for patients and 
physicians. Currently, there is a need to generate new quantitative method to assist in the diagnosis 
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and prognosis of prostate cancer by clinicians and pathologists. Troyer’s and coworkers used 
molecular preservation by extraction and fixation ("mPREF"), which includes a procedure to 
extract small molecules by liquid-liquid extraction using aqueous methanolic solvent.1 One of the 
main advantages of mPREF is the ease with which conventional histology can be performed on 
the same tissue. This unique feature of mPREF enables quantitation of small molecule metabolites.  
With this method, one can screen for prostate cancer to provide the biopsy sample with useful 
information on metabolites concentration change in the cancer-containing and non-cancer 
containing tissue samples. In a proof-of-principle studies, Troyer’s and coworkers identified eight 
significant metabolites [uracil, alanine, proline, malate, xanthine, betaine, N-acetyl aspartic acid 
(NAA) and N-acetyl-glucosamine (NAG) with concentration level difference between tumor and 
non-tumor samples. Currently there exists a need for analytical methods that permit the separation 
and quantitation of aforementioned polar metabolites.  Procedures utilizing gas chromatography 
(GC)4 or liquid chromatography (LC) 5,6 have been developed, but are restricted to the analysis 
limited biomarkers for detection of prostate cancer. In addition, for most of metabolites, the 
available LC or GC column could not meet the demand of separation selectivity. Most of the 
published HPLC methods are time consuming require expensive columns and employ gradient 
elution or multi-step separation and detection.  
Capillary electrochromatography (CEC)7 is a hybrid of HPLC and CE with the combination of 
advantages for both HPLC and CE techniques. In recent years, CEC has attracted more and more 
attention because of the benefits of low injection size in volume limited biological samples. Due 
to the flexibility of stationary phase, fritless design and excellent performance, the polymer 
monolith is one of the most suitable format in CEC. However, the low sample capacity in CEC 
and trace level analysis of small molecules in biological samples requires a high sensitivity 
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detector based on mass spectrometry (MS). The most popular ionization source for CEC is the use 
of electrospray Ionization (ESI).  With the help of sheath liquid and ESI source8, the ionic or polar 
compounds separated by the CEC under low flow conditions (low nL/min range) can be efficiently 
transferred from the liquid phase into gas phase ions required by MS instruments. In addition, ESI-
MS relies on the production of ions which are multiply charged. The newly emerging hyphenated 
technique such as CEC-MS distinguishes analytes by both their differences in electrophoretic 
mobilities and stationary phase retention whereas MS could detect the eluted compounds based on 
differences in mass-to-charge-ratio. Thus, CEC-MS combines the advantages of both CEC and 
MS providing high separation efficiency, determining molecular masses and/or structural 
information in one analysis.  
As mentioned earlier, previous research by Troyer et al. identified a subset of metabolites from 
prostate needle biopsy prepared using the mPREF method as potential prostate cancer diagnostic 
markers. These markers were stratified based on the analytical technique mostly applicable for 
metabolite quantitation to be used in future verification studies and possible diagnostic assay 
development. In this work, a CEC-MS assay is develop to quantitate eight proof of concept (POC) 
metabolites that are selected from the candidate list1 including betaine, malate, proline, NAA, 
NAG, uracil, xanthine, and alanine in human tissue biopsy extracts. The structure of metabolites 
is shown in Figure 2.1. 
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2.3 Experimental Section  
2.3.1 Chemicals and Reagents 
Vinylbenzyl trimethylammonium chloride (VBTA), Bisphenol A glycerolate dimeth-acrylate 
(BisGMA), 2, 2′- azobis (2-methylpropionitrile) (AIBN), 3-(trimethoxy-silyl)propyl methacrylate 
(γ-MAPS) were purchased from Sigma-Aldrich (St. Louis, MO). Ethylene glycol dimethacrylate 
(EDMA) purchased from Sigma-Aldrich was distilled to remove inhibitor before its usage. The 
HPLC grade acetonitrile (ACN), methanol (MeOH), triethylamine (TEA), butylamine (BA), 
valeric acid (VA), heptaflurobutyric acid (HFBA), and 7.5 M ammonium acetate (NH4OAc) 
aqueous solution, dimethyl sulfoxide (DMSO), alanine, uracil, malate, proline, NAA, NAG, 
betaine and xanthine were all obtained from Sigma-Aldrich (St. Louis, MO). All isotope labeled 
chemicals for the quantitation were obtained as follows, [D-alanine-2-d1, uracil-5-d1, N-
(carboxymethyl)-N,N,N-trimethyl-d3-ammonium Chloride (N-methyl-d3), D-proline-2,5,5-d3 
from CDN Isotopes]; malic acid- L-[14C(U)] and N-acetyl aspartic acid, DL-[2,3-3H] from ARC; 
xanthine- 13C-15N2 from Alsachim; N-acetyl-D-[1-13C] glucosamine from Omicron. Triply 
deionized water (TDI, 18.2 MΩcm) was generated in the laboratory using Barnstead Nanopure II 
Water System (Dubuque, IA). All the chemicals have above 98% purity. 
2.3.2 Preparation of Monolithic Columns 
Two different pretreatment procedures could be use to prepare the monolithic column. For the first 
procedure, a 60 cm long fused silica capillary (360 μm o.d., 100 μm i.d., Polymicro Technologies, 
Phoenix, AZ) was flushed under vacuum with acetone and 1 M NaOH for 15 min each. Next, the 
capillary was filled with 1 M NaOH and both ends were sealed with rubber septa and heated at 
100 °C for 2 h in a GC oven Finally, the capillary was flushed with triply deionized water, 1 M 
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HCl, triply deionized H2O, and MeOH for 15 min each under vacuum. A solution of γ-MAPS 
(50%, v/v in anhydrous MeOH) was then filled through the capillary under vacuum. The filled 
capillary was once again sealed with rubber septa and kept at 50 °C for 14 h in a GC oven.  
The second procedure also started with 60 cm long fused silica capillary (360 μm o.d., 100 μm 
i.d.). The capillary is flushed under vacuum with 1 M NaOH solution, triply deionized water, 0.1 
M HCl, triply deionized water and MeOH for 3, 0.5, 0.5, 0.5 and 0.5 hrs, respectively.  Next, the 
capillary is flushed under vacuum with HPLC grade anhydrous MeOH for 0.5 hrs. Finally, the 
capillary is flushed under vacuum with γ-MAPS (50%, v/v in anhydrous MeOH) for ~ 0.5hrs. The 
filled capillary sealed with rubber septa is then placed at 60 ◦C for 20 h in a GC oven.  
Both procedures were tested, and there were not much difference on the column performance. 
Most experiments in this study followed the second procedure. 
Next, the unreacted γ-MAPS solution was removed by flushing the capillary under vacuum using 
acetone for 5 min. The vinylized capillary was eventually dried under nitrogen for 3 h at 60 °C in 
a GC oven.  
A typical procedure for making monolithic columns is shown in Scheme 1 and described as 
follows. First, 10mg (10%, w/w) of the VBTA and 1 mg of AIBN were dissolved in a mixture 
containing various compositions of crosslinker (% w/w) of BisGMA and EDMA, Table 2.1).  
Table 2.1 Effect of binary crosslinker composition on physical  characteristics of monolithic 
columns. 
*Column 
Crosslinker: 
EDMA 
(wt%) 
Crosslinker: 
BisGMA (wt%) 
Porosity 
T  
Permeability 
(×10−15m2)  Ko 
EOF (cm2v-
1s-1) 
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A 20 0 0.81 3.63 6.43E-04 
B 15 5 0.74 2.68 6.19E-04 
C 10 10 0.70 2.38 2.97E-04 
D 5 15 0.65 2.26 1.78E-04 
E 0 20 0.93 5.25 3.23E-04 
* All columns A-E were polymerized using 10% (wt/wt) VBTA as functional monomer , 19% 
(wt/wt) methanol  and  51% ( wt/wt) of  dodecanol  as porogens ,  AIBN 1%. (wt/wt) as initiator 
 
To each of the mixture, porogens (dodecanol and MeOH) was added. The final polymerization 
solution was then ultrasonicated for 30 min before filling the solution to the pretreated capillary 
with a handheld syringe. Typically, in the preparation of CEC-MS column, 30 cm out of 60 cm of 
the pretreated capillary was filled. The column was then sealed with rubber septa and was kept at 
60 °C in a GC oven to polymerize. After 20 h of polymerization, the column was flushed with 
ACN for 24 h to remove the unreacted monomers. The monolithic capillary was conditioned for 
24 h with mobile phase before use. 
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Scheme 1. Synthetic scheme for the preparation of poly (VBTA-co-BisGMA/EDMA) monolithic 
column. The chemical structures of monomer and crosslinkers  are shown in the inset box to the 
left. R stands for the monomer VBTA. The letter m and n is the degree of polymerization. 
2.3.3 Morphology Measurements 
A Hitachi X-650 (Hitachi, Japan) scanning electron microscope (SEM), which is part of Georgia 
State University core facility, was used to characterize the microscopic morphology of the 
monolithic columns. Monolithic columns samples were cut to 2 mm in length and placed on an 
aluminum stub by double-sided carbon tape. The samples were then sputter-coated with 
gold/palladium alloy with a SPI sputter. 
2.3.4 CEC-MS/MS Instrumentation 
All CE experiments were performed on Agilent G7100 CE system (Agilent Technologies, Palo 
Alto, CA). Agilent QqQ MS/MS was used as a detector to collect all MS data was equipped with 
Agilent CE-MS adapter kit (G1603A), an Agilent CE-ESI-MS sprayer kit (G1607) and Agilent 
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20% Crosslinker (BisGMA/EDMA)
10% Monomer (VBTA)
70%Porogen (methanol and dodecyl alcohol)
1% Initiator (AIBN)
60 C for 24 h
H3CO Si
OCH3
OCH3
O
CH2
CH3
O
Si OH
O
Si OH
O
Si OH
Monolithic column bed
Si
O
CH3
O
Si O
O
Si O
O
Si O
EDMA R
m n
BisGMA R
m n
BisGMAEDMA
N
+
CHH2C
VBTA
31 
1100 series isocratic HPLC pump to deliver the sheath liquid with a 1:100 splitter. Nitrogen was 
used both as a nebulizing gas and drying gas. An Agilent 1100 LC equipped with MS/MS was 
used to optimize the MRM parameters of all analytes. A series III isocratic HPLC pump (Lab 
Alliance, State College, PA) was used to flush and condition the column. An Ultra-Plus II micro-
HPLC system (Micro-Tech Scientific Inc., Fontana, CA) was used for the measurement of porosity 
and permeability. 
2.3.5 Monolithic Column Conditioning 
After 20 h of polymerization, the column was flushed with ACN for 24 h to remove the unreacted 
monomers. The monolithic capillary was conditioned for 24 h with mobile phase before use. 
Before a monolithic column was installed in CE-MScartridge, the monolithic column was 
equilibrated with by stepwise voltage conditioning from 2-15 kV using CE-UV cartridge in which 
both ends were immersed in mobile phase.  At the completion of voltage conditioning, the 
monolithic column is quickly transferred from CE-UV to CE-MS cartridge and inserted in the CE 
nebulizer. Before installation of the capillary in the nebulizer, care is taken to ensure that the inlet 
lift of the CE instrument is in the upright position.  
2.3.6 Buffer and Analyte Preparation  
Various parameters were used to optimize the CEC-MS conditions to get best separation and 
detection as following: A series of BGEs containing 15 mM NH4OAc were studied over an 
extensive pH range from 2.5 to 11.0 in 1.0 unit increment. Because the natural (unadjusted) pH of 
15 mM NH4OAC is 6.8), for pH lower and higher than the unadjusted pH value, 1 M acetic acid 
and 1 M ammonium hydroxide was used to obtain the desired pH of the BGE. The unadjusted pH 
of BGEs containing HFBA, BA, TEA and VA were 1.7, 10.0, 11.0 and 3.3, respectively. Acetic 
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acid and ammonium hydroxide were used to adjust the pH to 1.8. The mobile phases, which 
contains a mixture of 50% – 90% (v/v) ACN, 15 mM HFBA at pH 1.8 were prepared as follows. 
Aliquots of 0.195mL of HFBA and 0.133 mL of 7.5M NH4OAc were mixed with a certain 
percentage of ACN and water in a 100 mL centrifuge tube. The aqueous-organic mixture is then 
vortex, sonicated and degassed.  Stock solutions of each standard POC metabolite standards were 
prepared at 50 mM by dissolving in TDI. Working analyte solutions were prepared at 500 μM by 
diluting the analyte stock solution into 50/50 ACN/H2O (v/v).  Injections were performed 
electrokinetically at +5 kV for 10 sec.  Analytes strcture and predicted propertity is shown in Figure 
2.1. 
 
Figure 2.1 Chemical structures of all POC metabolites. 
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2.3.7 Calculations 
The chromatographic retention factor was calculated using the following equation:  
m
mR
t
tt
k

'  (1) 
where k’ is the retention factor for neutral compounds, tR and tm are the retention times of the 
analyte and the dead time marker (DMSO), respectively. 
For ionic compounds, a modified equation was used 
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In equation (2) k* is the electrochromatographic retention factor, ep is the electrophoretic 
mobility of the charged solute and eo  is the electroosmotic mobility. ep  and eo  were obtained 
from open tubular column. 
The porosity of the CEC monolithic columns was calculated by the following method. The porosity 
experiment was carried out on a micro-HPLC system, in which the volumetric flow rate V (m3/s) 
was measured by weighing the mobile phase (pure ACN) flowing through the column in a certain 
amount of time. The linear velocity of the mobile phase u (m/s) was measured by taking a ratio of 
column length with an untrained dead time marker. The porosity was calculated by the following 
equation: 
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Where εT is the total porosity of the column; r (m) is the inner radius of the column.  
The specific permeability of the monolithic column was calculated by: 
p
Lu
K T


0
 (4) 
where η (Pa s) is the dynamic viscosity of the mobile phase; L (m) is the effective length of the 
column; Δp (Pa) is the pressure drop along the column. 
2.4 Results and Discussion 
2.4.1 Characterization of monolithic columns 
VBTA is positively charged compound with quaternary ammonium and a vinylbenzyl group, 
which was widely used as a monomer in monolith to provide ion interaction and π- π interaction 
with analytes. 9-11 Lin’s10 group has synthesized a monolithic column with VBTA as a monomer 
and hydrophilic BisGMA as a crosslinker and successfully applied into the separation of polar 
analytes such as uracil, uridine, adenine, etc. in CEC with UV detection. To achieve simultaneous 
separation of the targeted metabolites in the biopsy extracts, the percentage of binary crosslinker 
(EDMA and BisGMA) were carefully optimized the get the best monolith stationary phase 
compatible for CEC-MS/MS. Five possible recipes of polymerization mixture with the various 
ratio (% w/w) of EDMA and BisGMA) were used to make monolithic columns as shown in Table 
2.1. The data listed in Table 2.1 suggest that binary mixture of crosslinkers of EDMA-BisGMA 
provide lower porosity (
T
) and permeability (Ko) compared to the use of single crosslinker. The 
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column permeability follows the order: column E >column A> column B> column C. >column D. 
Thus, BisGMA is more permeable than EDMA as a single crosslinker, but increasing the ratio of 
BisGMA decreases the porosity and permeability as well as electroosmotic flow (EOF).The SEM 
photographs of the five monolithic CEC columns under the optimum polymerization conditions 
are shown in Figure 2.2. From the SEM micrographs, one can observe that the spherical units are 
agglomerated into clusters in column A-D, and monolith was successfully formed in the CEC 
capillary with through pores evenly distributed and homogeneous. By comparing A1 and D1, the 
through-pore size decreased along with the increase in BisGMA from around 5µm to 1µm. For 
column A-D the through pore size decreases as shown in the SEM pictures of each column. A 
conclusion could be made that along with the through-pore size decrease and polymer cluster size 
decrease, the open space in the monolith become less and more difficult for fluid (ACN) to move 
through the column.  
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Figure 2.2 Scanning electron micrographs (SEMs) of monolith columns with different 
crosslinker ratio.  A: EDMA:BisGMA 20:0; B:  EDMA:BisGMA 15:5; C: EDMA:BisGMA 
10:10; D: EDMA:BisGMA 5:15; E: EDMA:BisGMA 0:20. Detailed information of the 
polymerization mixture composition for the monolith is described in Table 2.1. A-1 and A-2 
represents the SEM picture s of polymer monolith and the edge section of polymer and the capillary 
inner wall of column A, respectively. The SEM scale bar was measured as follows: A-1 (10μm), 
A-2 (2μm), B-1 (2μm), B-2 (2μm), C-1 (2μm), C-2 (2μm), D-1 (10μm), D-2 (2μm), E-1 (100μm), 
E-2 (2μm).  
 
At 10:10 BisGMA: EDMA ratio (Figure 2.2C) a gap between the monolith and capillary inner 
wall appeared and was progressively worse with the increase in BisGMA content (Figure 2.2 E). 
When the column E was flushed with ACN to get rid of unreacted porogens, a piece of white solid 
clump was observed to fall off. In particular, Figure 2.2 E-2, shows a significant gap inside the 
capillary column, due to swelling of monolith. For the column E, the sudden high porosity and 
permeability in Table 2.1 is related to hollow morphology inside the column, which is more like a 
thin layer coated column instead of real monolith formation.  
The overlaid plots of the back pressure vs. the volumetric flow rate observed on the five monolithic 
columns are shown in Figure 2.3. Consistent with the lowest values of porosity T and permeability 
Ko in Table 2.1, the column D with a ratio of 5:15 for EDMA-BisGMA provided the highest back 
pressure, i.e., the slope of pressure vs. flow rate is the steepest. On the other hand, column E with 
only BisGMA as a crosslinker has significantly lower back pressure, consequently much shallower 
slope. Nevertheless, it is obvious that the linearity of back pressure to flow rate for all five plots is 
very good, which means the mechanical stability of monolithic column A-D monolithic columns 
is excellent under the pressure of even 25 Mpa. 
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Figure 2.3 Plots of the applied pressure against the volumetric flow rate of ACN in the micro-
HPLC experiment. Mobile phase: pure ACN.   The composition of each columns are described 
in  Table 2.1. 
 
From the evidence on column characterization, column C-E was eliminated from the list due to 
the inhomogeneous polymer monolith. Column A was also not under consideration because the 
BisGMA percentage is 0 and lack of hydrophilic group on the monolith important for the 
separation selectivity of POC polar metabolites. More data will be presented in the following 
section to support this decision.  
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2.4.2 Mobile Phase Optimization 
2.4.2.1 Effect of Mobile Phase pH 
A series of BGEs containing 15 mM NH4OAc were studied over a pH range from 2.5 to 11.0 in 
1.0 unit increment, as shown in Figure 2.4. At pH lower than 2.0, the silanol groups on the surface 
of column are protonated. At pH 2.5-6.0, metabolites alanine, proline, and NAG are neutral, while 
xanthine and uracil positive are changed and malic acid negative charged, showing a flat profile, 
except for betaine which exists as a zwitterionic compound at pH five due to ionization of 
carboxylate group, which perhaps interacts with positive charges on the VBTA monolith. 
Interestingly, between pH 7-8, separation factor drops for all metabolites due to increasing in t0 
value (Figure 2.4). Another drop was seen for all analytes between pH 10-11 for the same reason 
of decreased t0 value.  
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Figure 2.4 Effect of the buffer pH values on the retention factors of eight POC metabolites. 
Conditions: CEC-ESI-MS/MS using monolith poly (VBTA-co-BisGMA/EDMA). The 
experiment was performed on 60 cm(100 μm I.D.). Running buffer: 75/25 ACN/water, 15mM 
NH4OAc, pH varies; Voltage: +15 kV; Capillary temperature, 20 °C. Injection: 5 mbar, 100 s; MS 
conditions: sheath liquid, MeOH/H2O (80/20, v/v) containing 40 mM HOAc; sheath liquid flow 
rate, 5 μL/min; capillary voltage, +3500V; drying gas flow rate, 5.0 L/min; drying gas temperature, 
200 ◦C; nebulizer pressure, 7 psi. 
 
When pH is lower than 2.5, a large amount of acetic acid was added to adjust the pH and the 
monolithic bed start deteriorating after around 20 runs due to the high salt concentration in the 
buffer. Therefore, another BGE such as HFBA was introduced in the lower pH range because of 
its lower pKa and compatibility to MS. The separation of metabolites are shown using HFBA at 
three different pH values are shown in Figure 2.5. Clearly, a decrease in mobile phase pH from 2.5 
to 1.8 increases the resolution between two peak pairs (betaine/xanthine) and 
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(proline/acetylaspartic acid) to 1.45 and 2.30, respectively. As a result, pH 1.8 was chosen as the 
optimum pH for the CEC-MS of POC metabolites. 
 
Figure 2.5 Effect of mobile phase pH on simultaneous separation of eight proof of concept 
(POC) metabolites. Conditions: CEC-ESI-MS/MS using monolith poly (VBTA-co-
BisGMA/EDMA). Experiment  was performed on 60 cm(100 μm I.D.). Running buffer: 75/25 
ACN/water, 15mM heptflurobutyric acid, (a). pH= 4.0, (5). pH= 2.5, (c). pH= 1.8, Voltage: +15 
kV; ; Capillary temperature, 20 °C. Injection: 5 kV 10s; ESI-MS conditions are the same as Figure 
3. Peak identification: (1) dimethylsulfoxide; (2) uracil; (3) malate; (4) alanine; (5) betaine; (6) 
xanthine; (7) proline; (8) acetylaspartic acid; (9) acetylglucosamine.  
 
2.4.2.2 Effect of Acetonitrile 
The percentage of ACN was varied from 50% (v/v) ACN to 90% (v/v) ACN to optimize the run 
time and separation of POC metabolites. The k* of metabolites was calculated based on different 
ACN percentage in the buffer. In Figure 2.6, the k* of all compounds increase nearly two folds 
with the increase of ACN. A conclusion could be drawn that hydrophilic interaction seems to be 
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the primary mechanism of interaction between solutes and the monolithic column. The use of 75% 
(v/v) of ACN was chosen as the optimum organic solvent percentage due to a good compromise 
between analysis time and resolution of the metabolites.  
 
Figure 2.6 Effect of The of percent acetonitrile on retention factors of eight POC metabolites. 
Conditions: CEC-ESI-MS/MS using monolith poly (VBTA-co-BisGMA/EDMA). Experiment 
was performed on 60 cm(100 μm I.D.). Running buffer: ACN/water varies, 15mM 
heptflurobutyric acid, 5mM NH4OAcpH= 1.8, Voltage: +15 kV; ; Capillary temperature, 20 °C. 
Injection: 5 kV 10s; ESI-MS conditions are the same as Figure 2.3. 
 
2.4.2.3 Effect of Volatile BGE 
As mentioned in the previous section, the use of volatile BGE as i mobile phase additive also had 
an influence on column performance. Two bases (TEA and BA), one salt (NH4OAC), and two 
acids (VA and HFBA) were used as mobile phase additives and tested at the optimum pH and % 
(v/v) of ACN. Figure 2.7 showed different resolution for the POC metabolites with different 
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additives. For example, the use of acid in the mobile phase showed better selectivity for two 
pairs of compounds, ALA/BET and BET/XAN. In addition, PRO/NAA acid pair was slightly 
better resolved using HFBA compared to the use of VA in the mobile phase. 
 
 Figure 2.7 Effect of volatile mobile phase additives for on simultaneous separation of eight 
POC metabolites. Conditions: volatile additive was performed on 60 cm (100 μm I.D.) poly 
(VBTA-co-BisGMA/EDMA) monolithic column. Running buffer: ACN/water 75/25, additive 
varies, pH= 1.8, Voltage: +15 kV;Capillary temperature, 20 °C. Injection: 5 kV 10s; ESI-MS 
conditions are the same As Figure 2.3. 
 
Furthermore, the use of acids provided slightly longer run time but overall better separation 
selectivity compared to the use of TEA, BA and NH4OAC. The S/N of metabolites with different 
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types of additive in the mobile phase compared in Figure 2.8 shows that HFBA provides the 
highest S/N, resulting in us get lower LOD. Overall, the use of HFBA in the mobile phase could 
have baseline separation for all metabolites and less suppression of MS signal.  
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Figure 2.8 Effect of types of volatile additive in the mobile phase on S/N of eight POC in CEC-ESI-MS. Conditions: CEC-ESI-
MS/MS using monolith poly (VBTA-co-BisGMA/EDMA) column 60 cm (100 μm I.D.).   Running buffer: 75/25 ACN/water, 15mM 
heptflurobutyric acid, pH= 1.8, Voltage: +15 kV; Capillary temperature, 20 °C. Injection: 5 kV 10s; ESI-MS conditions are the same 
as Figure 2.3. 
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2.4.3  Comparison of CZE-MS, Open Tubular CEC-MS and Monolithic CEC-MS 
A standard mixture of 8 POC metabolites was separated by monolith poly (VBTA-co-
BisGMA/EDMA) CEC, VBTA coated CE (open tubular CEC) and bare silica CE. The comparison 
was performed in the optimized buffer condition for each column. Figure 2.9A shows the 
comparison of eight metabolites, in which the monolith poly (VBTA-co-BisGMA/EDMA) 
provided better separation selectivity and symmetrical peak shapes for metabolites mixture 
(Fig.9A) compared to CZE-MS or open tubular CEC-MS  Although significant lower run times of 
POC metabolites were observed with CEC-MS and CZE-MS, the use of former provided 
separation of only DMSO (EOF marker peak) from the other eight metabolites, whereas the use of 
later provided only two distinct peaks. These results confirmed that CEC-MS with monolithic is a 
significantly useful tool to improve the separation selectivity of metabolites with very similar z/m. 
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Figure 2.9 Comparison of the separation of 8 POC under optimized mobile phase on (a). 
VBTA monlotihic column, (b). VBTA coated column and (c).bare silica column. Conditions: 
(a). CEC-ESI-MS/MS using monolith poly (VBTA-co-BisGMA/EDMA). Experiment was 
performed on 60 cm (100 μm I.D.). Running buffer: 75/25 ACN/water, 15mM heptflurobutyric 
acid, pH= 1.8, Voltage: +15 kV; Capillary temperature, 20 °C. Injection: 5 kV 10s; ESI-MS 
conditions are the same as Figure 3; b). CEC-ESI-MS/MS using VBTA coated column. Running 
buffer: 15mM NH4OAc, pH =1.8. Other conditions are the same as (a). (c). CE-ESI-MS/MS using 
bare silica column. Running buffer: 15mM NH4OAc, pH =1.8. Other conditions are the same as 
(a). Peak identification: (1) dimethylsulfoxide; (2) uracil; (3) malate; (4) alanine; (5) betaine; (6) 
xanthine; (7) proline; (8) N-acetylaspartic acid (NAA); (9) N-acetylglucosamine (NGG).  
 
2.4.4 Comparison of Metabolites Separation with Varied Crosslinker Ratio 
To test our hypothesis that hydrophilic interaction is the primary retention mechanism for 
metabolites, the CEC of POC metabolites were separated with two crosslinkers (EDMA-BisGMA) 
ratio. A comparison of chromatogram in Fig. Ten show that optimum ratio of BisGMA: EDMA is 
5:15. Increasing the amount of hydrophilic crosslinker (BisGMA) compared the hydrophobic 
crosslinker (EDMA) decreased the separation of polar metabolites (Figure 2.10 C-D). In addition, 
the use of GMA or EDMA alone cannot provide separation of all eight polar metabolites. Thus, 
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Figure 2.10 confirmed our assumption that column B with a binary crosslinker ratio of 15:5 for 
EDMA: BisGMA is indeed the best monolithic column for CEC-MS separation. This column 
provided the desired peak shape, selectivity, and efficiency, compared to the use of other 
monolithic columns. 
 
Figure 2.10 Chromatograms showing comparison of composition of crosslinker in the 
monolith. Conditions: CEC-ESI-MS/MS using monolith poly (VBTA-co-BisGMA/EDMA). 
Experiment  was performed on 60 cm(100 μm I.D.). Running buffer: 75/25 ACN/water, 15mM 
heptflurobutyric acid, pH= 1.8, Voltage: +15 kV; Capillary temperature, 20 °C. Injection: 5 kV, 
10 s; ESI-MS conditions are the same as Figure 2.3. Peak identification are the same as Figure 9. 
2.4.5 Method Validation 
2.4.5.1 Intraday and Interday Repeatability 
Compared to LC-MS, CE-MS using open tubes has the disadvantage with unstable flow rate and 
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the electrospray. Using the charged monomer VBTA, a stable and high EOF could be obtained to 
drive the mobile phase through the monolithic column bed. The top part of Table 2.2 shows 
intraday repeatability for 30 consecutive runs with a good % RSD of tr and k* in the range of 1.6-
4.6 and 1.4-3.7, respectively.  
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Table 2.2 RSD values for tr, k' and S/N for intraday (n = 30) study. 
˦Conditions: CEC-ESI-MS/MS using monolith poly (VBTA-co-BisGMA/EDMA) was performed 
on 60 cm (100 μm I.D.). Running buffer: 75/25 ACN/water, 15mM hepta flurobutyric acid, pH= 
1.8; Other CEC-MS/ESI-MS conditions are the same as described in figure 6 (a). 
 
The interday % RSD for three consecutive days (n =15 runs each day) for tr, k* and S/N was found 
in the range of 1.6-4.6, 1.4-3.7 and 3.0-6.4, respectively (Table 2.3). As expected, the intraday and 
interday repeatability for S/N was slightly higher in the range of 2.9-6.2 and 3.0-6.4, respectively.   
 
 
Table 2.3 RSD values for tr, k' and S/N for interday  (n = 15, 3 days) study. 
 % RSD %RSD % RSD 
Compounds tR k S/N 
uracil 1.6 1.4 3.0 
 % RSD %RSD % RSD 
Compounds tR k S/N 
uracil 1.6 1.4 2.9 
malate 2.3 2.0 4.2 
alanine 2.2 1.9 6.2 
betaine 4.2 3.7 4.3 
xanthine 3.9 3.5 3.5 
proline 3.5 3.1 4.6 
NAA 4.6 4.0 5.1 
NAG 2.3 2.0 4.2 
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malate 2.4 2.1 4.3 
alanine 2.3 2.0 6.4 
betaine 4.3 3.8 4.4 
xanthine 4.1 3.5 3.6 
proline 3.6 3.2 4.8 
NAA 4.8 4.2 5.3 
NAG 2.4 2.1 4.4 
˦Conditions: CEC-ESI-MS/MS using monolith poly (VBTA-co-BisGMA/EDMA) was performed 
on 60 cm (100 μm I.D.). Running buffer: 75/25 ACN/water, 15mM hepta flurobutyric acid, pH= 
1.8; Other CEC-MS/ESI-MS conditions are the same as described in figure 6 (a). 
The column to column repeatability experiment was carried out on three different monolithic 
columns with very good % RSD for tr, k* and S/N in the range of 1.7-5.4, 1.5-4.7 and 3.4-6.5, 
respectively (Table 2.4). Interestingly, the % RSD for S/N for alanine is somewhat higher on the 
same column on three different days as well on three different columns on the same day suggesting 
the alanine signal was somewhat unstable in the electrospray compared to other polar analytes.  
Table 2.4 RSD values for tr, k' and S/N for column to column  (n = 15, 3 columns) precision 
study. 
 % RSD %RSD % RSD 
Compounds tR k S/N 
uracil 1.7 1.5 3.4 
malate 2.6 2.2 4.9 
alanine 2.5 2.2 6.5 
betaine 4.9 3.8 4.9 
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 % RSD %RSD % RSD 
xanthine 4.6 3.6 4.0 
proline 4.0 3.5 4.9 
NAA 5.4 4.7 5.4 
NAG 2.6 2.2 4.3 
˦Conditions: CEC-ESI-MS/MS using monolith poly (VBTA-co-BisGMA/EDMA) was 
performed on 60 cm(100 μm I.D.). Running buffer: 75/25 ACN/water, 15mM hepta flurobutyric 
acid, pH= 1.8; Other CEC-MS/ESI-MS conditions are the same as decribed in Figure 2.4. 
 
2.4.5.2 Robustness 
To examine whether the column performance would be affected by small variations in mobile 
phase and ESI-MS conditions, a robustness test was designed by using fractional factorial design 
(Dodde 11.0 software) The experimental multivariate design included the simultaneous 
investigation of five CEC-ESI-MS parameters (mobile phase pH, mobile phase ACN percentage, 
sheath liquid flow rate, nebulizer pressure and ESI voltage) were changed by 5% to 15% (Table 
2.5).  
Table 2.5 Fractional factorial design and  the level of factors  (Central, low, and high) values 
of each parameter chosen for the robustness study. 
Factor m.p. pH 
m.p. 
ACN% 
SL flow rate 
(uL/min) 
Nebulizer Pressure 
(psi) 
ESI voltage 
(V) 
-1 1.5 66.5 7.6 6 3325 
0 1.8 70 8 7 3500 
1 2.1 73.5 8.4 8 3675 
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Factor m.p. pH 
m.p. 
ACN% 
SL flow rate 
(uL/min) 
Nebulizer Pressure 
(psi) 
ESI voltage 
(V) 
Factor 
Range ±15% ±5% ±5% ±15% ±5% 
 
A total of 19 experiment were carried out, 11 trials were set at the middle of the investigational 
ranges and 8 trials were designed in combinations with the extreme values (Table 2.6).  
Table 2.6 Fractional factorial design and experimental design and the corresponding 
response. 
m.p. pH % (v/v) ACN SL Flow Rate 
Nebulizer 
Pressure 
ESI Voltage S/N Area Resolution 
1.5 66.5 7.6 8 3675 5864 6441 1.39 
2.1 66.5 7.6 6 3325 5980 6432 1.35 
1.5 73.5 7.6 6 3675 5861 6555 1.38 
2.1 73.5 7.6 8 3325 5963 6541 1.37 
1.5 66.5 8.4 8 3325 5847 6437 1.36 
2.1 66.5 8.4 6 3675 5821 6455 1.35 
1.5 73.5 8.4 6 3325 5803 6465 1.39 
2.1 73.5 8.4 8 3675 5891 6421 1.37 
The impact of the five parameters was estimated with three responses Rs of betaine/xanthine pair, 
S/N and peak area of betaine. Figure 2.11 shows the scaled and centered coefficients for the study 
output of S/N, peak area of betaine and the betaine/xanthine resolution. A confidence level of 99% 
was obtained with good % RSD of 4.2, 3.1 and 4.7 for S/N, Rs and peak area, respectively. In this 
coefficient plot, if the error bar falls into the parameter bar, it means this term is significtant. In 
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our case, the positive error bars are much higher than the top of the parameter bar and negative 
error bars are much lower than the bottom of the parameter bar, which means the term is not 
significant. The figures illustrates that the small change does not make much difference to the 
separation and the detection. 
 
Figure 2.11 Scaled and centered coefficients for the studied outputs (S/N ratio, peak area, 
and resolution of betaine and xanthine) as a function of the parameters: pH, ACN%, SL flow 
rate (SLFR), nubulizer pressure (NP), ESI voltage  (VESI). 
 
A final consideration was to test the column lifetime for the repeatability of POC metabolite 
analysis. A series of 115 consecutive runs were performed on the monolithic column. The run-to-
run repeatability was maintained with % RSD of less than 4.7. In addition, the peak asymmetry 
are maintained over more than one hundred consecutive analysis (Figure 2.12).   
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Figure 2.12 Column life time of poly-(VBTA-co-BisGMA/EDMA) monolithic columns. 
Separation of all eight POC metabolites were obtained by setting up automated 115 runs sequence 
on  the  CE 710 instrument 
 
2.4.6 Analytical Figures of Merit  
The quantitation of this study was performed with isotope labeled internal standards (IS). The 
calibration curves were obtained based on the peak area ratio between metabolites to IS versus the 
concentration of standard samples.  Linearity of the calibration curve were tested in the range of 
0.3-50 µM (Figure 2.7).  
Compounds Calibration curve R2 
Linear range 
(μM) 
LOD 
(μM)* 
LOQ 
(μM)* 
Alanine y = 0.02169x + 0.0122 0.9996 0.3-50 0.05 0.25 
Uracil y = 0.0219x + 0.0097 0.9995 0.3-50 0.05 0.20 
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Compounds Calibration curve R2 
Linear range 
(μM) 
LOD 
(μM)* 
LOQ 
(μM)* 
Betaine y = 0.0205x + 0.0036 0.9996 0.3-50 0.05 0.10 
Xanthine y = 0.0212x + 0.0430 0.9990 0.3-50 0.05 0.10 
ÏMalate y = 0.0019x -0.0007 0.9916 0.3-50 0.10 0.30 
Proline y = 0.0236x + 0.02377 0.9997 0.3-50 0.10 0.25 
NAA y = 0.0257x - 0.0014 0.9998 0.3-50 0.05 0.25 
NGG 
y = 0.02336x + 
0.05431 
0.9993 0.3-50 0.05 0.20 
 
The linear regression were calculated using model equation y=ax+b, where x is the metabolites to 
IS peak area ratio and y is the analytes concentration. From the calibration curve, the correlation 
coefficient R2 in the range of 0.9990-0.9998 for all analyte (except for malate). The LOD for most 
of metabolites was 50 nM except for malate and proline with LOD of 100 nM, due to the relatively 
low ionization and MS/MS response. A typical LOD chromatogram for all POC metabolites is 
shown in Figure 2.13. The LOQ for those metabolites is 100 nM-300 nM, which means this method 
is sensitive enough to quantitate almost all POC metabolites at nanomolar levels. 
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Figure 2.13 Chromatogram of metabolites separation  of all eight POC metabolites at the 
limit of detection.  Peak identification is the same as described in Figure 2.12. 
 
2.4.7 Application to the Analysis of Biopsy Extracts of Prostate Tissue  
Before quantitation of the POC metabolites in prostate tissue, the biopsy extracts were 
preconcentrated by ten folds. The procedure is shown in Figure 2.14. Briefly, each 0.6 mL of 
methanol extracted sample was transferred to a 1.5 mL vial and dried under a gentle air flow at 
room temperature for around 3 hours. The residue was reconstituted with 60 µL of 50/50 (v/v) 
MeOH /water in the same vials. The mixture was centrifuged for 20 min, and a 50 µL aliquot of 
the resulting supernatant was transferred 
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sample to be 100uL in 50/50 ACN /water. 
 
Figure 2.14 Prostate needle biopsy extracts preparation procedure. 
 
The validated method and the calibration curve was used in the determination of POC metabolites 
concentration in prostate biopsy extract. The sample (extracted by mPREF) was provided by Dr. 
Dean Troyer’s (Eastern Virginia Medical School). A total of 22-sample set as normal/tumor pairs 
were from the same patient. In this pair of sample, one sample is from the tumor containing part 
of prostate biopsy and the other one is from the healthy part of prostate. However, note that the 
classification of normal vs. diseased was unspecified and all samples were received in the coded 
form, and therefore this final analysis is considered as a blind test. Thus, we applied our validated 
method without knowing whether the sample is tumor containing or not. After we got the 
concentration data, the data was send back to EVMS for the clinical diagnostic results. At least 21 
out of 22 pairs of sample match the clinic results and accuracy of 95.5% for this study is 
remarkable. A representative comparison chromatogram between two samples for one 
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normal/tumor pair is shown in Figure 2.15. As expected, each POC metabolites had higher S/N in 
tumor tissue compared to normal tissue.  
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Figure 2.15 EIC chromatogram of metabolite distribution in biopsy extracts in cancer versus noncancer biopsy extracts. 
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One could easily tell the concentration difference between two paired sample with the bar plot in 
Figure 2.16. Two trends are obvious: First, concentration of all metabolites are higher in cancer 
vs. non-cancer human subjects. Second, concentration of two metabolites (alanine and proline) 
were highest among all metabolites irrespective of disease states.  
 
Figure 2.16 Concentration levels between normal vs. tumor biopsies extracts. Analysis 
Conditions are the same as Fig 2.5 
A box plot of the concentration range between tumors versus normal prostate tissue extracts is 
shown in Fig. 17. Note that there is some overlap of concentration range between NEG and POS 
tumor group. This is mainly because the metabolites in this study not only participate the 
metabolism in prostate, but also involved in other pathways. For example, if a certain metabolite 
is active in other pathways of metabolism, the concentration of this metabolite may be higher in 
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this patient healthy prostate than other patient’s tumor containing prostate biopsy. 
 
Figure 2.17  Box plots of tumor versus normal POC metabolite concentrations in biopsies 
extracts. POS indicates the presence of cancer; NEG indicated the absence of cancer; Study is 
based on 21 (tumor /non-tumor) pairs 
 
2.5 Concluding remarks 
A CEC-MS/MS platform for the quantitation of POC metabolites was successfully developed. 
First, the use of best monolithic column with favorable porosity and permeability was optimized. 
Second, to improve the separation selectivity of eight POC metabolites, mobile phase parameters 
(buffer pH, volume fraction of acetonitrile and buffer additive) were studied to improve the 
separation selectivity and S/N.  Using 15mM HFBA in 75/25 ACN/water buffer at pH 1.8 baseline 
separation of all eight POC metabolites were achieved in less than 6.5 min.  The combined use of 
a VBTA-co-BisGMA/EDMA monolith and a triple quadrupole MS provided a simple and 
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compatible hyphenation method with high repeatability of migration times and S/N for selective 
and sensitive MS/MS detection of all metabolites. 
Compared to bare silica and open tubular coated column, the CEC-ESI-MS/MS method using the 
VBTA-co-BisGMA/EDMA monolith was the best method because it provided better separation 
selectivity, symmetrical peak shapes and more rugged CE-MS for analysis of POC metabolites 
mixture. The ruggedness studies performed suggest that there is potential to develop CEC-MS 
with monolithic column as an efficient diagnostic tool to routinely measure the concentration of 
small metabolites in biopsy extracts of prostate tissue samples. 
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3 CHAPTER 3: Use of linear solvation energy relationships for capillary 
electrochromatographic retention: Application on Retention behavior and selectivity of 
neutral solutes on surfactant bonded monolith columns and insight into chiral 
recognition mechanism in enantioselective analysis  
3.1 Abstract 
As a useful tool linking the intermolecular interaction contribution to the retention of neutral 
molecules is linear solvation energy relationships (LSERs).   This tool is known to predict the 
retention behavior and selectivity in high-performance liquid chromatography.   This is a first 
article in which we propose to use LSERs to understand chiral recognition of amino acid based 
surfactant monolithic columns in CEC. This study includes two sections. In the first section, eight 
different amino based surfactant monomers were synthesized, with different chain length, linker 
type or head groups. Solutes retention behavior of a set of 31 neutral solutes were characterized 
and compared using LSER.  . The system parameters (aka. system coefficients) of eight monolithic 
columns were characterized and the results indicate that the LSER is an excellent approach to the 
selectivity of neutral compounds for capillary electrochromatography (CEC). In the second section, 
one of the chiral monolithic column, poly (AADCL-co-EDMA was chosen, and a set of seventeen 
chiral compounds were screened on this chiral stationary phase (CSP). Next, the A-V descriptors 
of a set of 17 chiral compounds along with the system coefficient of poly (AADCL-co-EDMA) 
was used to calculate the separation factor (i.e., k' predicted).   At least six out of 17 chiral 
compounds were found to have k' predicted of the second eluted enantiomer generated by LSER 
equation matched with the experimental retention factor value.   By calculating the delta x system 
of coefficients of six molecular enantiomers, it was possible to predict the enantioselectivity which 
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was found to be an excellent agreement with the experimental determined enantioselectivities.  
This study indicated the possibility to use LSER as a potential tool to get insights into chiral 
recognition mechanism. 
3.2 Introduction  
Linear solvation energy relationships (LSERs) are relationships between solute retention behavior 
and the numerical measures of analytes properties. The LSERs equation are routinely used to 
understand the relationships between molecular interactions that control the retention and 
selectivity in gas chromatography (GC), high performance liquid chromatography (HPLC), 
supercritical fluid chromatography (SFC) and micellar electrokinetic chromatography (MEKC).    
The aim of LSERs studies in chromatography is to understand the intermolecular processes 
controlling retention.   By generating LSERs model, we could predict the experimental retentions 
quantitatively to achieve an acceptable separation. To systematically characterize stationary phase 
in chromatographic studies, a thermodynamic parameter, i.e. the solute retention factor in the form 
of log k’, is used, which associates with the solute descriptors in a given separation system using 
system constants (aka. system parameters).  These coefficients measures the magnitude of 
difference between the stationary phase and the mobile phase but the solute descriptors are 
independent of the chromatographic system. Numerous tables of solute descriptors have been 
published.1 Chromatographic system (mobile and stationary phase, temperature) is calibrated 
using solutes with known descriptors to establish its system parameters. Once the later are known, 
the retention factors of any solute whose LSERs descriptors are unknown can be predicted.  
Equation (1), which  is one of the more widely accepted equation forms of the LSERs model is 
expressed as follows:   
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logk=c+eE+sS+aA+bB+vV   (1) 
in which k is the solute retention factor ((tR −t0)/t0). In the above equation, the capital letters A, B, 
E, S and V are the solute descriptors, whereas the lower-case letters (a, b, e, s and v) are the system 
constants. As mentioned earlier, the A-V solute descriptors are only related to the solute and 
independent of the mobile and/or the stationary phase used.  On the other hand, a-v system 
constants reflects the difference in solute interactions between the mobile phase and the stationary 
phase. Figure 3.1 is a cartoon picture showing a LSERs. The capital letter A represents for the 
solute hydrogen bond acceptor ability, whereas B is the solute hydrogen bonding accepting ability. 
Thus, the overall aA and bB terms are H-bond interactions, a is the system parameter for basicity 
interactions with acidic A solutes and b is the system parameter of acidity interactions with basic 
B solutes.  The E descriptor represents for the molar refraction due to n or/and π electrons in the 
molecule structure. Hence, the eE term represents polarizibility (induced dipole) type interactions. 
The term S is the solute descriptor for the polarizability and dipolarity of the molecule.   Hence, 
the sS term is a component of polarizibility interactions. The fifth descriptor, V stands for the 
molecular cavity formation energy, calculated using the solute structure.2 Thus, the overall term 
vV represents hydrophobic or dispersive interactions. 
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Figure 3.1 Linear solvation energy relationship model: solute descriptors and interactions 
related to stationary phase. The monolithic stationary phase is marked in grey color and the 
interaction (retention) of the stationary phase is characterized by measuring the sum of 
system coefficients  (represented by lower case letters a,b, e, s and v) at the top , and solute 
descriptors (represented by upper case letters, A, B, E, S and V) at the bottom. 
 
In the LSERs, two enantiomers share the same solute descriptor values, which means the 
enantiomers would not be separated by achiral stationary phase. Instead, enantiomers could be 
separated on a chiral stationary phase (CSP). As mentioned by Mitchell et al.3-6, the less retained 
enantiomer of the enantiomeric could be considered as reference solute to model the 
enantioselectivity factor α using modified the LSERs equation as follows, 
logk2 -logk1 = logα= ∆eE+∆sS+∆aA+∆bB+∆vV    (2) 
in which, k1 and k2 are the retention factors of first and second eluting enantiomer, respectively. 
The ∆xX terms indicate the difference of enantiomer/CSP interactions. As this equation is based 
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on the difference of intermolecular interactions for enantioselectivity, good understanding on 
equation 2 could give an insight into the chiral recognition mechanism and predict whether chiral 
compounds could be separated on certain chiral stationary phase (CSP).   
In the first part of this project, retention measurements of 31 achiral solutes have been carried out 
on eight amino acid bound monolithic CSP. The chain lengths, head group, and linker types are 
compared to evaluate similarities and differences among these CSPs for the determination of 
LSERs system parameters or system constant.  The original column poly (10-acryl-
amidodecenoxy carbonyl-L-leucine-co-EDMA) column was made by our group with an amino 
acid surfactant serves as chiral monomer of CSP.7 A set of different amino acid surfactant were 
synthesized are used as monomer in the formation of surfactant bound polymer monolithis. The 
chemical structure of eight surfactants 8-acrylamidooctenoxy carbonyl-L-leucine (AAOCL), 10-
acryl-amidodecenoxy carbonyl-L-leucine (AADCL), and 12-acryl-amidododecenoxy carbonyl-L-
leucinate (AADoCL), 10-acryl-amidodecenoxy carbonyl-L-alanine (AADCA), 10-acryl-
amidodecenoxy carbonyl-L-valine (AADCV), acrylamidoundecanoyl-L-alanine  (AAUA), 
acrylamidoundecanoyl-L-valine (AAUV) and acrylamidoundecanoyl-L-leucine (AAUL) are 
shown in Figure 3.2 and was originally reported by Shamsi’s group.7 
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Figure 3.2 scheme for polymerization of amino acid based surfactant monolithic column. 8 
columns used in this study  are as follows:  poly-(AAOCL-co-EDMA), poly-(AADCL-co-
EDMA), or poly-(AADoCL-co-EDMA) monoliths with monomer linker X=C, head group 
R=leucine, and carbon number n = 8, 10, and 12, respectively;  poly-(AADCV-co-EDMA) 
and poly-(AADCA-co-EDMA) monoliths with monomer linker X=C, carbon number n = 10, 
and head group =valine and alanine, respectively; poly-(AAOCV-co-EDMA) and poly-
(AAOCA-co-EDMA) and poly-(AAOCL-co-EDMA)  monoliths with cross linker X=O, 
carbon number n=8, head group R=valine, alanine and leucine, respectively. The letters , b, 
c, m and  n are the aggregation numbers. 
 
The interactions, contribustion to enantioseparation is discussed in section II.  Thus, in the seond 
part of this project, 42 chiral compounds were screened on poly-AADCL-co-EDMA column and 
17 chiral compounds were separated. The experimental retention factor value of two enantiomers 
will be compared to the predicted retention factor value, which is calculated by the LSERs equation 
generated in part one.   As most chiral compounds are ionic in pH 5.0 mobile phase, a modified 
equation was used. 
eoep
eoepk
k


/1
/'
*


   (3) 
In which k* is the electrochormatographic retention factor, ep is the electrophoretic mobility and 
eo  is the electroosmotic mobility. 
8 
n= 8,10 or 12
X=O or CH2
R= Leucine, Valine, Alanine
AIBN, porogens (MeOH, ACN 
and water) 60°C 20h
+
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 If one enantiomer has identical value of predicted and experimental retention factor, the other 
enantiomer’s retention factor and solute descriptors could be used to generated a second LSERs 
equation, which means the enantiomers are considered to interact with different CSP domains.9  
Capillary electrochromatography (CEC) combines the excellent selectivity of high-performance 
liquid chromatography (HPLC) with the superior efficiencies of capillary electrophoresis (CE). 
Varied stationary phase in CEC includes packed column, coated column, silica-based and 
polymer-based monolith columns. Due to the high permeability, high surface area for reactivity, 
high repeatability and flexible choice of function group on CSP, polymer-based monolith column 
were chosen for this study. 7,10,11 The aim of this work is to develop a retention model for the 
characterization of eight amino acid surfactant bound monolithic columns.  Furthermore, we 
selected AADCL as a model monolithic column to evaluate chiral interactions because previous 
work in Shamsi’s group has shown good chiral selectivity for this particular monolithic column.7 
3.3 Experimental 
3.3.1 Reagents and Materials 
2,2′-azobis(2-methylpropionitrile) (AIBN), 3-(trimethoxy-silyl)propyl methacrylate (γ-MAPS), 
10-amino-1-decanol, 8-amino-1-octanol, 12-amino-1-dodecanol, and triphosgene were obtained 
from TCI-America (Portland, OR).  Ethylene glycol dimethacrylate (EDMA) purchased from 
Sigma-Aldrich was distilled to remove inhibitor before its usage. The HPLC grade acetonitrile 
(ACN), methanol (MeOH), triethylamine (TEA) and 7.5 M ammonium acetate (NH4OAc) aqueous 
solution, dimethyl sulfoxide (DMSO), benzene, toluene, ethylbenzene, propylbenzene, 
butylbenzene were purchased from Sigma-Aldrich (St. Louis, MO).  Other chemicals used for the 
synthesis of surfactant monomer, such as pyridine, anhydrous Na2SO4, L-leucine, 
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dichloromethane, sodium bicarbonate, sodium hydroxide, hydrochloric acid, and ethyl acetate 
were also purchased from Sigma-Aldrich.  Ethanol (HPLC grade) was purchased from Fisher 
Scientific (Fair Lawn, NJ). Triply deionized water (18.2 MΩcm) was generated in the laboratory 
using Barnstead Nanopure II Water System (Dubuque, IA).  The achiral and chiral compounds 
used in this study were purchased from Sigma-Aldrich. All the chemicals have the purity of 98% 
or higher and were used as received without further purification unless specifically noted.  
3.3.2 Preparation of Monolithic Columns  
A 40 cm long fused silica capillary (360 μm o.d., 100 μm i.d., Polymicro Technologies, Phoenix, 
AZ) was flushed under vacuum with acetone and 1 M NaOH for 15 min each. The capillary was 
then filled with 1 M NaOH and both ends were sealed with rubber septa and heated at 100 °C for 
2 h in a GC oven. Next, the capillary was flushed with triply deionized water, 1 M HCl, triply 
deionized H2O, and MeOH for 15 min each under vacuum. A solution of γ-MAPS (50%, v/v in 
anhydrous MeOH) was then filled through the capillary under vacuum. The filled capillary was 
once again sealed with rubber septa and kept at 50 °C for 14 h in a GC oven. Next, the unreacted 
γ-MAPS solution was removed by flushing the capillary under vacuum using acetone for 5 min. 
The vinylized capillary was eventually dried by nitrogen for 3 h at 60 °C in a GC oven.   
A typical procedure for making AADCL monolithic columns is described as follows.  First, 15 mg 
of AADCL and 0.5 mg of AIBN were dissolved in a mixture containing various compositions (% 
wt/wt) of dimethyl ether, ACN, MeOH, and H2O as porogens. To each of the porogen mixture, 
14.3 μL of EDMA was added. The final polymerization solution was ultrasonicated for 30 min 
and filled into the pretreated capillary using a hand held syringe. Typically, in the preparation of 
CEC-UV column, 30 cm out of 40 cm of the pretreated capillary was filled. The column was then 
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sealed with rubber septum and was kept at 60 °C to polymerize. After 20 h of polymerization, the 
column was flushed with ACN for ~2 h to remove the unreacted monomers. The on-column 
detection window was then burned in the empty segment of the capillary adjacent to the packed 
monolithic bed and 8.5 cm to the outlet end of the capillary for CEC-UV experiment. The column 
was eventually cut to obtain a total length of 33.5 cm with a monolithic bed of 25 cm (from the 
inlet end). The monolithic capillary was conditioned for 24 h with running buffer before use.  
3.3.3 Instrumentation 
Agilent CE station(Agilent Technologies, Palo Alto, CA) equipped with an auto sampler, 0-30 kV 
power supply, and a diode-array UV detector was used to carry out all the CEC experiment. Agilent 
3D-CE ChemStation software (Rev. A. 08.04) was used for data acquisition and analysis. A series 
III isocratic HPLC pump (Lab Alliance, State College, PA) was used to flush and condition the 
column.  An Ultra-Plus II micro-HPLC system (Micro-Tech Scientific Inc., Fontana, CA) was 
used for the measurement of porosity and permeability. All LSERs modeling were performed on 
SAS (9.3). 
3.4 Results and Discussion 
3.4.1 Achiral Solutes and LSERs Equation Generation 
The retention behavior of 31 achiral test solutes was examined in each monolithic column and 
compared to generate the LSERs model. Due to the high UV absorption, a set of benzene derivative 
with known molecular descriptors (Table 3.1) were chosen to determine system constants of Eq. 
1 for the eight monolithic columns.12 Based on the solute descriptor value on hydrogen bonding 
ability (parameters A and B), the solutes are divided into 3 sets,  hydrogen bond donors (HBDs) (A 
≥B), nonhydrogen bond donors (NHBs) (B ≤0.20) and  hydrogen bond acceptors (HBAs) (solutes 
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13-23, B ≥ 0.22).13 trends for HBD, NHB and HBA solutes are showin in a series of 
electropherograms in Figure 3.3-3.4, C1-C4.   The effect of chain length of monolithic column on 
separation of HBD is shown in Figure 3.3.  
 
Figure 3.3 Effect of chain length of monolithic column on separation of hydrogen bond 
donors (HBD). Peak identification: (1). benzyl alcohol, (2). phenol, (3). 4-ethylphenol, (4). 4-
fluorophenol, (5). 4-chloropheno, (6). 4-bromopheno, (7). 3-chlorophenol, (8). 3-
bromophenol. 
 
With the increase in carbon chain length from 8 to 12, the retention of all HBD solutes increase 
without any alteration in separation selectivity. Effect of the head group and -linker type of the 
monolithic column on separation of HBD is shown in Figure 3.4.  
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Figure 3.4 . Effect of head group and linker types of  surfactant-bound monolithic column 
on separation of hydrogen bond donors (HBD). Peak identification: (1). benzyl alcohol, (2). 
phenol, (3). 4-ethylphenol, (4). 4-fluorophenol, (5). 4-chloropheno, (6). 4-bromopheno, (7). 3-
chlorophenol, (8). 3-bromophenol. 
 
By comparing the retention of solutes with same monomer head group but different cross-linker, 
a conclusion could be made that the surfactant linker containing oxygen has less retention on the 
solutes than linker with methylene groups. With the carbamate linker, the hydrophobicity of the 
monolithic column is higher than the amide monomer.  As a result, the retention of achiral solutes 
are longer in carbamate (AADCL, AADCV, and AADCA) monolith over amide (AAUL, AAUV, 
and AAUA) monolith.  The monomers head groups (leucine, alanine, and valine) have ascending 
retention to the solutes. The same trend was found on NHB solute sets (Figure C1-C2) and HBA 
(Figure C3-C4).   
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This is mainly because of the structure and molecular volume difference of head group. With 
DMSO as the t0 marker, retention factor of all solutes were calculated. Using the solute descriptor 
values tabulated in in Table 3.1, the LSERs equation coefficients for eight different stationary 
phase were calculated. All coefficients are discussed separately under a subheading in the order it 
is mentioned in LSER equation (1). 
Table 3.1 Solute descriptors of 31 achiral compounds. 
  V S A B E 
Solute descriptors Nonhydrogen bond donors (NHD)   
1 Benzene 0.716 0.61 0.52 0 0.14 
2 Toluene 0.857 0.601 0.52 0 0.14 
3 Ethylbenzene 0.998 0.613 0.51 0 0.15 
4 Propylbenzene 1.139 0.604 0.5 0 0.15 
5 p-Xylene 0.998 0.613 0.52 0 0.16 
6 Chlorobenzene 0.839 0.718 0.65 0 0.07 
7 Bromobenzene 0.891 0.882 0.73 0 0.09 
8 Iodobenzene 0.975 1.188 0.83 0 0.12 
9 4-Chlorotoluene 0.98 0.705 0.67 0 0.07 
10 Biphenyl 1.324 1.36 0.99 0 0.22 
11 Naphthalene 1.085 1.36 0.92 0 0.2 
12 1-Methylnaphthalene 1.226 1.344 0.9 0 0.2 
 Hydrogen bond acceptors (HBA)   
13 Acetophenone 1.014 0.818 1.01 0 0.48 
14 Benzonitrile 0.871 0.742 1.11 0 0.33 
15 Methyl benzoate 1.073 0.733 0.85 0 0.46 
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  V S A B E 
16 Ethyl benzoate 1.214 0.689 0.85 0 0.46 
17 4-Chloroanisole 1.038 0.838 0.86 0 0.24 
18 4-Nitrotoluene 1.032 0.87 1.11 0 0.28 
19 4-Chloroacetophenone 1.136 0.955 1.09 0 0.44 
20 Methyl 2-methylbenzoate 1.214 0.772 0.87 0 0.43 
21 Phenyl acetate 1.073 0.661 1.13 0 0.54 
22 3-Methylbenzyl alcohol 1.057 0.815 0.9 0.33 0.59 
23 Phenethyl alcohol 1.057 0.784 0.83 0.3 0.66 
 Hydrogen bond donors (HBD)   
24 Benzyl alcohol 0.9160 0.8030 0.8700 0.3300 0.5600 
25 Phenol 0.7750 0.8050 0.8900 0.6000 0.3000 
26 4-Ethylphenol 1.0570 0.8000 0.9000 0.5500 0.3600 
27 4-Flourophenol 0.7930 0.6700 0.9700 0.6300 0.2300 
28 4-Chloroaniline 0.9390 1.0600 1.1300 0.3000 0.3100 
29 4-Bromophenol 0.9500 1.0800 1.1700 0.6700 0.2000 
30 3-Chlorophenol 0.8980 0.9090 1.0600 0.6900 0.1500 
31 3-Bromophenol 0.9500 1.0600 1.1500 0.7000 0.1600 
 
3.4.2 System parameters for chiral monolithic columns  
Table 3.2 compares the system parameters obtained for eight monolithic columns with different 
chain lengths (AAOCL, AADCL, AADoDCL), head groups (AADCL, AADCV, AADCA) and 
linker type (AADCL vs. AAUL). In LSERs equation, a larger value of coefficient associated with 
each descriptor represents a stronger interaction between solutes and stationary phase or mobile 
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phase. For example, solute-stationary phase interactions are positive for positive coefficient values 
whereas solute-mobile phase interactions are negative for negative coefficient values associated 
with the solute descriptors.  
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Table 3.2 Comparison of system constants for eight surfactant-bound monolithic columns of different chain length, head 
group and linker. 
monomer e s a b v c r2 n 
AAOCL 1.3567 -0.6714 -0.9477 2.0583 0.8931 -1.8845 0.985 31 
SE 0.09614 0.01144 0.02323 0.21002 0.23885 0.11625   
AADCL 1.7301 -0.4681 -0.8953 2.2301 0.346 -0.3219 0.996 31 
SE 0.06516 0.0067 0.01109 0.09419 0.01362 0.01588   
AADoCL 1.9878 -0.1909 -0.8052 2.9129 0.2435 -1.5251 0.975 31 
SE 0.12641 0.00657 0.01742 0.21509 0.21853 0.09428   
monomer e s a b v c r2 n 
AADCA 1.08837 -0.2056 -0.9749 1.8411 0.98046 -1.1185 0.984 31 
SE 0.09805 0.01164 0.0227 0.22874 0.24347 0.1185   
AADCV 1.43045 -0.0933 -0.7036 2.0417 0.72428 -1.691 0.992 31 
SE 0.13024 0.00676 0.01729 0.23654 0.22499 0.09705   
monomer e s a b v c r2 n 
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AAUL 1.57148 -0.1394 -0.2159 2.974 0.48473 -1.7844 0.995 31 
SE 0.08013 0.00566 0.0103 0.1055 0.1088 0.0483   
AAUA 1.33867 -0.1223 -0.2405 2.78226 0.88067 -2.08 0.988 31 
SE 0.12058 0.00975 0.02112 0.25623 0.31647 0.08258   
AAUV 1.75949 -0.0699 -0.203 2.84954 0.54756 -1.9214 0.979 31 
SE 0.16017 0.00566 0.0161 0.26501 0.29245 0.06   
SE: standard error; r2: regression coefficient; n: number of achiral solutes in the regression. 
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3.4.2.1 Coefficient c 
Under a closer look into every coefficient, the coefficient c is an independent system parameter 
and not solute related. Instead, c is related to column phase ratio and varies with column nature 
and experiment temperature.4  As for all CSP, the coefficient c is negative, which means for any 
solutes, all eight stationary phase is less retentive than other CSP stationary with positive c value. 
As c value does not count in solute selectivity, it will not be further discussed.   
3.4.2.2 Coefficient a 
Coefficient a represents the interaction of H-bond basic character, which shows the second greatest 
variation among all coefficients, indicating high basic capability of the column structure.  
3.4.2.3 Coefficient b 
The coefficient b is the largest positive coefficient and bonding between acidic solutes and 
surfactant carbonyl group attached to the hydrocarbon chain as amide or carbamate spacer, which 
is related to the basic character of solute (B descriptor). With most polar interactions, the solutes 
favor the stationary phase.  
3.4.2.4 Coefficient e and s 
The e and s coefficients link the polarizability and dipole dipole interaction contributing to the 
selectivity. A negative value of s represents for the negative contributes of dipole-dipole 
interaction between the solutes and stationary phase. Thus, ompared to stationary phase, the solutes 
favors mobile phase.  
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3.4.2.5 Coefficient v 
The cavity formation and disperation interaction, coefficient v, is the third most significant 
parameter contributing to retention.  As for different head group monomer, the head group alanine, 
valine and leucine has an increasing molecular volume, which will effect on the polymer structure 
of monolith. One can observe that as the head group volume increases, the coefficient v decrease, 
which may be because that the smaller head group could form the proper cavity for the achiral 
solute. The relatively small v value is because all the solutes in this study does not have a large 
range of atom numbers, which reduced the influence of molecular volume.  
3.4.3 Comparision of coefficient values 
The three most significant coefficient appear to be "b" "e" and "v".  The bar plots comparing the 
effect of chain length, head group and linker type for system constant is shown in Figure 3.5. In 
the comparison of solutes between each columns, one could found with the increasing of monomer 
chain length from 8-12, the e-coefficient increased from 1.36 to 1.98, which means the interactions 
between π and n electrons is a leading interaction when the chain length is longer. As the monomer 
changed among alanine, leucine and valine, a and b values has a great change (23% and 21%), 
which is mainly because the monomer head group structure varied, leading to the hydrogen-
bonding interaction change. When the crosslinker changes from methylene group to oxygen atom 
attached to carbonyl, the hydrophobicity of the stationary phase changed and the e-coefficient also 
decreased. Because b, e and v are three most significant contributor to retention, the discussion 
here is organized accordingly after constructing plots as suggested above. 
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Figure 3.5 Bar plots showing system constants for eight surfactant-bound monolithic columns of different chain length, head 
group and different linker. 
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3.4.4 Test Compounds of Chiral LSERs Equation 
A set of 42 chiral compounds were chosen to be tested on poly-AADCL-co-EDMA monolithic 
column. Out of all chiral compounds, seventeen chiral solutes were selected because they showed 
some degree of enantioseparation, including pindolol, metoprolol, cateolol, alprenolol, oxprenolol, 
atenolol, propranolol, pseudoephedrine, ephedrine, methylephedrine, norphenylephedrine, 
norepinephrine, benzoin, verapamil, nefopam, hexobarbital and terbutaline. The retention factor, 
selectivity and resolution are shown in Table 3.3. 
Table 3.3 Resolution, selectivity and retention factors of chiral compounds separated on poly 
(AADCL-co-EDMA) monolith column. 
Compounds Rs Selectivity α k1® k2® predicted k* 
Pindolol 0.42 1.0123 2.60 2.69 3.0716 
Cateolol 0.33 1.0211 0.75 0.76 2.8412 
Alprenolol 0.94 1.1126 1.04 1.08 1.2236 
Oxprenolol 1.12 1.2122 0.74 0.77 1.0671 
Atenolol 0.91 1.0231 1.04 1.12 1.2896 
Ephedrine 1.51 1.2342 1.04 1.09 1.2686 
Benzoin 0.25 1.0124 0.04 0.17 1.5590 
Verapamil 1.32 1.2144 0.46 1.09 1.2710 
Nefopam 1.22 1.2078 0.51 1.78 0.9850 
Hexobarbital 1.35 1.2122 0.06 0.59 0.9670 
Terbutaline 1.51 1.3294 0.76 0.77 0.9490 
Metoprolol  0.21 1.0241 2.04 2.08 2.0839 
Pseudoephedrine 1.45 1.2901 1.35 1.74 1.7413 
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Methylephedrine 1.22 1.1450 1.35 1.55 1.5455 
Propranolol 1.25 1.0841 2.33 2.52 2.5245 
Norepinephrine 0.91 1.0725 1.35 1.45 1.4476 
Norphenylephedrine 1.26 1.4551 0.86 1.25 1.2518 
® k1 and  k2 are obtained from experiment, as described in Step 3 of Figure 3.5; * Predicted k  was 
calculated as described in Step 2 of Figure 3.6.   
3.4.5 LSER Study of the Enantiomer-AADCL Interactions 
To To generation the chiral LSERs equation, one need to first build the LSERs model based on 
the experimental k’ and solutes descriptors of achiral compounds, which is shown in Table 3.2. 
Second, the predicted logk’ value will be calculated by using the LSERs model equation and chiral 
solutes descriptor. After that, one need to compare the predicted logk2’ with the experimental 
logk2’. If the predicted k and experimental k value matches, the first enantiomer would be consider 
to have a different set of coefficient. If there are six chiral solutes, which matches the predicted 
logk2’ with the experimental logk2’, it would be possible to calculate out another LSERs equation 
with first eluted enantiomer. By using Eq. 2, the logα could be concluded and all ∆x terms could 
be determined. 
After the test of all 17 chiral compounds, a set of experiment were performed with the same solutes 
and mobile phase but bare silica column. The corrected retention factor were calculated to 
eliminate the influence of ionic interaction. A detailed procedure to determine the coefficient value 
of chiral LSER is shown in Figure 3.6. Propranolol, pseudoephedrine, methylephedrine, 
norphenylephedrine, norepinephrine, metoprolol were found to match the predicted logk2’ with the 
experimental logk2’.  
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Using the LSER model equation  to calculate the log k’ of chiral 
solutes with known solute descriptors.
Build the LSER model based on the experimental k’ and solutes
descriptors of achiral compounds with SAS software.*
e.g. insert the solute descriptors  in the equation in step 1,  the log 
of predicted retention factor.  Fore  example, pseudoephedrine log 
k’=0.2405, thus for pseudoephedrine , the  predicted retention 
factor k’=1.7412
logk’=-0.3219+1.7301E+0.3460V-0.4680S-0.8953A+2.2301B
Run the chiral compounds on the column and compare the 
predicted log k’ with the experimental log k’. 
For pseudoephedrine, experimental retention factor k1 =1.35 and 
k2=1.74 ; experimental k2 =predicted k2
Use equation logα= log k2 –log k1 = ∆eE+∆sS+∆aA+∆bB+∆vV =(a2-
a1)A+(b2-b1)B+(e2-e1)E+(s2-s1)S+(v2-v1)V+c2-c1; a1, b1, e1, s1, v1 and c1
are obtained from Step 4; a1, b1, e1, s1, v1 and c1 are obtained from
Step 4; ; a2, b2, e2, s2, v2 and c2 are obtained from Step 1;.
Log α= 0.129E+0.0114S+0.0171A+0.1259B+0.015V+0.1302
Step 2
Step 3
Step 5
Step 1
Screen more chiral compounds; For compounds experimental k2
=predicted k2 , collect all the experimental k1 values; With known
chiral solutes descriptor, generate the LSER equation with SAS.
Six chiral solutes (propranolol, pseudoephedrine, ethylephedrine, 
norphenylephedrine, norepinephrine, metoprolol) with known 
descriptors (A, B, E, S,V) and experimental k1 was used to calculate 
the coefficient a1, b1, e1, s1, v1 from LSER,
log k1’=-0.4521+1.6011E+0.3310V-0.4795S-0.9142A+2.1042B
Step 4
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Figure 3.6 The procedure of enantioselectivity prediction using LSER model. * The 
experiment was based on poly (AADCL-co-EDMA) monolith column. 
A new set of LSERs coefficient were generated and all ∆x terms were calculated as shown in Table 
3.4. Among all six parameters, e and b coefficient has the greatest value, suggesting Interactions 
between π and n electrons and hydrogen-bonding interaction with basic solutes are the dominating 
interactions for chiral recognition. 
Table 3.4 Comparison of coefficient values of LSER equation on first and second eluted 
enantiomers. 
 e s a b v c 
logk1 1.6011 -0.4795 -0.9124 2.1042 0.331 -0.4521 
**logk2 1.7301 -0.4681 -0.8953 2.2301 0.346 -0.3219 
 ∆e ∆s ∆a ∆b ∆v ∆c 
logα 0.129 0.0114 0.0171 0.1259 0.015 0.1302 
** coefficient values e2, s2, a2, b2, and v2  from step 1  discussed in Figure 3.6;  
A new set of LSERs coefficient were generated and all ∆x terms were calculated as shown in Table 
3.4. Among all six parameters, e and b coefficient has the greatest value, suggesting Interactions 
between π and n electrons and hydrogen-bonding interaction with basic solutes are the dominating 
interactions for chiral recognition. 
Table 3.5 lists the A–V solute descriptors for the representative six enantiomers. By setting six 
simultaneous equation in LSER to obtain the equation for first eluting enantiomer, the retention 
factor and selectivity would be obtained. Six chiral solutes (propranolol, pseudoephedrine, 
ethylephedrine, norphenylephedrine, norepinephrine, metoprolol) with known descriptors (A, B, 
E, S,V) and experimental k1 was used to  calculate the coefficient a1, b1, e1, s1, v1 from LSER.  
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Table 3.5 LSER solute descriptors of six molecular enantiomers *. 
 E S A B V r2 SE 
Metoprolol  0.320 1.133 0.610 0.297 1.450 0.955 0.042 
Pseudoephedrine 0.310 0.118 0.780 0.114 1.410 0.986 0.023 
Methylephedrine 0.290 0.249 1.020 0.196 1.310 0.965 0.027 
Propranolol 0.320 0.250 1.090 0.299 1.440 0.963 0.026 
Norepinephrine 0.260 0.185 1.210 0.345 1.210 0.972 0.024 
Norphenylephedrine 0.320 0.138 1.210 0.300 1.210 0.963 0.023 
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When screening the chral compounds and compare the experimental retention factor with the 
predicted retention factor, three different cases were observed. Case (i) the retention factors 
predicted by LSER matches the first eluting enantiomer retention factor; Case (ii) the LSER 
predicted retention factors matches the second eluting enantiomer retention factor; Case (iii) the 
LSER predicted retention factors did not correspond to either enantiomer. From retention 
mechanical, it can be illustrated that that in Case (i), the chiral stationary phase has overall 
attractive enantioselective interactions with the second enantiomer; in Case (ii), the mobile phase 
has overall attractive enantioselective interactions with the first enantiomer; in Case (iii), 
enantioselective interactions of the chiral stationary phase are with both enantiomers. The matched 
retention factor compounds are shown in Figure 3.6 
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Table 3.6 LSER data for five components of enantioselectivity factors and enantioselectivity. 
 ∆eE ∆sS ∆aA   ∆bB ∆vV Predicted logαÏ  Predicted α Experimental α 
Metoprolol  0.041 0.013 0.01 0.037 0.022 0.00847 1.020 1.024 
Pseudoephedrine 0.04 0.001 0.013 0.014 0.021 0.11024 1.289 1.290 
Methylephedrine 0.037 0.003 0.017 0.025 0.02 0.05997 1.148 1.145 
Propranolol 0.041 0.003 0.019 0.038 0.022 0.03402 1.082 1.084 
Norepinephrine 0.034 0.002 0.021 0.043 0.018 0.03104 1.074 1.073 
Norphenylephedrine 0.041 0.002 0.021 0.038 0.018 0.16241 1.454 1.455 
Ï Calculated from LSER equation (2), logα= logk2 -logk1 = ∆eE+∆sS+∆aA+∆bB+∆vV. 
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The chiral separation for the matched six enantiomers are shown in Figure 3.7.  The resolution and 
selectivity factor are listed in the figure. Although for the enantiomers, the resolution values vary 
from 0.21 to 1.45, they could still be inserted into the LSER equation and the linearity is from 
0.955 to 0.986, shown in Table 3.5 
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Figure 3.7 Chiral separation on poly-AADCL-co-EDMA monolithic column. 
Knowing the A–V solute descriptors (Table 3.5, top) and the coefficient a-v are obtained as shown 
in Figure 3.4, it is easily to calculate ∆xX terms as shown in Table 3.6. A visual radar plot could 
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help us to understand the interactions and enantioselectivity between the CSP and solutes, as 
shown in Figure 3.8 easily obtained. The five terms of Eq. (2) form a branch of a star in Figure 
3.8. This representation clearly show the strong positive contribution of the e term, the weak 
contribution of the s term and also, the significant contribution of the b term. All six radar plots 
showing the similar trending with the strong contribution e and weak contribution s. Also, the term 
b is the second contributed item, except for pseudoephedrine, due to the lower descriptor B. 
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Figure 3.8 . Radar plots showing the five components of the enantioselectivity factors of 
molecular enantiomers separated on poly-(AADCL-co-EDMA) monolith. 
3.5 Conclusion 
LSERs studies can give the insight into chiral recognition when enantiomer get separated on the 
monolithic the CSP. It was found the enantiomers behavior on the same CSP are different and two 
sets of LSER coefficient could be generated. In addition, interactions between π and n electrons 
and hydrogen-bonding interaction with basic solutes are the dominating interactions for chiral 
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recognition. Thus, one could expect a set of enantiomer with higher n electrons and high hydrogen 
bonding accepting ability would have higher enantioselectivity potential. 
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